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The epidermal growth factor receptor is overexpressed in up to 60% of ovarian epithelial malignancies. EGFR regulates complex
cellular events due to the large number of ligands, dimerization partners, and diverse signaling pathways engaged. In ovarian
cancer, EGFR activation is associated with increased malignant tumor phenotype and poorer patient outcome. However, unlike
some other EGFR-positive solid tumors, treatment of ovarian tumors with anti-EGFR agents has induced minimal response.
While the amount of information regarding EGFR-mediated signaling is considerable, current data provides little insight for the
lack of eﬃcacy of anti-EGFR agents in ovarian cancer. More comprehensive, systematic, and well-deﬁned approaches are needed
to dissect the roles that EGFR plays in the complex signaling processes in ovarian cancer as well as to identify biomarkers that can
accurately predict sensitivity toward EGFR-targeted therapeutic agents. This new knowledge could facilitate the development of
rational combinatorial therapies to sensitize tumor cells toward EGFR-targeted therapies.
1.Introduction
Epithelial ovarian cancer, deﬁned as cancers arising either
from the mesothelial lining of the ovaries (either from the
epithelial surface lining or cortical ovarian cysts formed by
invaginationsofthesurfaceepithelium)orfromthefallopian
tube epithelium [1], accounts for 90% of ovarian malig-
nancies [2]. Epithelial ovarian cancers are further divided
into 5 histologic subtypes: serous, endometrioid, mucinous,
clear cell, and undiﬀerentiated. Aberrant epidermal growth
factor receptor (EGFR) expression is detected in up to 60%
of ovarian cancers and occurs in all histologic subtypes
[3, 4]. Further, aberrant EGFR expression is associated with
poor outcome of ovarian cancer patients [5, 6]. In this
article, we review the EGFR family, the role of EGFR in
ovarian cancer, and the methods used to determine this
role. We also summarize the results of anti-EGFR therapies
in ovarian cancer clinical trials and discuss challenges and
future work in eﬀective treatments utilizing anti-EGFR
therapies in ovarian cancer, focusing on epithelial ovarian
cancer whenever possible.
1.1. The Epidermal Growth Factor Receptor Family. The
EGFR family (also known as the HER or ERBB family)
consists of 4 members: EGFR, HER2, HER3, and HER4
(alternately known as ERBB1–4). Structurally, the EGFR
family consists of an extracellular ligand binding domain, a
single transmembrane-spanning region, and an intracellular
region containing the kinase domain (Figure 1;r e v i e w e d
in [7–10]). In humans, more than 30 ligands have been
identiﬁed that bind to the EGFR family, including EGF and
EGF-like ligands, transforming growth factor (TGF)-α,a n d
heregulins (HRGs, also known as neuregulins) [11].
EGFR is activated upon ligand binding, which results in
aconformationalchangeintheextracellulardomain,leading
to homo- or heterodimerization with another EGFR family
member. The EGFR binding partner appears to depend
on several properties, including the proportion of EGFR2 Journal of Oncology
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Figure 1: Structure of EGFR. EGFR consists of extracellular, trans-
membrane, and intracellular domains. The extracellular domain is
the least conserved domain among the EGFR family members and
consists of 4 subdomains—two ligand-binding domains and two
receptor dimerization domains, which are cysteine-rich (reviewed
in [12]). The transmembrane domain, which spans the cell
membrane, is hydrophobic. The cytoplasmic tail of the EGFR
family is highly conserved and contains the tyrosine kinase domain.
Activation of EGFR family members leads to autophosphorylation
of the tyrosine residues in the cytoplasmic tail. The phosphorylated
tyrosine residues become docking sites for proteins with SRC
homology 2 and phosphotyrosine binding domains, which trans-
duce the signals downstream. EGFR phosphorylation at selected
residues and their functional outcomes are indicted in the diagram.
T: threonine; Y: tyrosine.
family members in the membrane, type and proportion of
ligand (reviewed in [10, 13]), and cell lineage likely reﬂected
in the expression of additional members of the signaling
complex (see below). Strikingly, HER2 is the preferred
binding partner for all EGFR family members [14], while
HER3 is an obligatory partner [15], being inactive on its
own or as a homodimer as it lacks intrinsic kinase activity
due to mutation of critical amino acids in the kinase domain
[16, 17]. This combination has lead to the suggestion by
Yarden and colleagues that HER2 and HER3 are “deaf and
dumb” members of the EGFR family, functioning in normal
physiology as part of signaling complexes with other EGFR
family members [18].
Activation of the EGFR family members results in trans-
duction of EGFR signals, via intracellular cascades, such as
mitogen-activated protein kinases (MAPKs), and AKT (also
knownasproteinkinaseB),resultinginperturbationofmul-
tiple cellular responses including proliferation, diﬀerentia-
tion, cell motility, and survival (reviewed in [9, 19]). A sum-
mary of selected EGFR family pathways is shown in Figure 2.
The EGFR family members can also be activated by other
signaling proteins independent of addition of exogenous
EGFR ligands. These include other receptor tyrosine kinases
(RTKs) such as insulin-like growth factor-1 receptor (IGF-
1R) (reviewed in [20, 21]) and tyrosine kinase receptor B
(TRKB, [22]) as well as other types of receptors such as
G protein-coupled receptors (GPCRs) (reviewed in [23]),
the leptin receptor [24], and adhesion proteins such as E-
cadherin (reviewed in [25]) and integrins (reviewed in [26]).
While the details of EGFR transactivation upon crosstalk
are not yet fully elucidated, transactivation has been shown
to occur by a variety of mechanisms. For example, there
is evidence that EGFR can be transactivated by IGF-1R by
direct binding [27]. Additionally, EGFR transactivation by
GPCR has been shown to occur intracellularly, such as by
activation of SRC upon GPCR stimulation (e.g., [28]), as
well as extracellularly, such as by GPCR activation by gastrin
releasingpeptide[29].ThisinducestheformationofaGPCR
complex containing SRC, Phosphatidylinositol 3 -kinase
(PI3K), PDK1, and TNF-α converting enzyme (TACE),
resulting in activation and translocation of TACE to the
membrane where it releases the EGFR ligand amphiregulin,
resulting in subsequent EGFR activation [29]. Lysophos-
phatidic acid (LPA)-GPCR-induced ectodomain shedding of
pro Heparin Binding-EGF also activates EGFR [30]. LPA-
mediated signaling is of particular importance in ovarian
cancer as abnormalities in LPA metabolism and function
likely contribute to initiation and progression of ovarian
cancer [31–33]. Additionally, TRKB may also play a role in
ovarian cancer as its activation has been shown to enhance
migration and proliferation and suppress anoikis in human
ovarian cancer cells [22, 34].
1.2. EGFR in Ovarian Cancer. The EGFR gene, located
on chromosome 7p12, is ampliﬁed in ovarian cancer in
approximately 4%–22% of cases [3, 6, 35, 36], including
about 13% in epithelial ovarian cancers [35]. Activating
EGFR mutations, as determined by sequence analyses of
potential activating mutation sites in the catalytic domain,
is rare in ovarian cancer, with a frequency of 4% or less
[6, 35, 37]. The constitutively active mutant EGFRvIII,
while reported earlier to be detected in 73% (24/32) of
ovarian cancers [38], was not detected in subsequent and
more extensive studies examining serous [6]o rv a r i o u s
types of ovarian cancers [39]. Overexpression of the EGFR
protein has been detected in 9%–62% of human ovarian
cancers [6, 36, 40, 41]; the diﬀerences in frequencies from
these studies likely reﬂect utilization of diﬀerent antibodies
and cutoﬀs for overexpression. EGFR gene ampliﬁcation or
protein overexpression occurs across all epithelial ovarian
cancer histotypes [3, 4]. Increased EGFR expression has
been associated with high tumor grade [3, 5, 6], high cell
proliferation index [6], aberrant P53 expression [6], and
poor patient outcome [5, 6].Journal of Oncology 3
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Figure 2: Selected representation of canonical EGFR family signaling pathways. The EGFR family consists of 4 members: EGFR, HER2,
HER3, and HER4 (indicated by numbers 1–4 in the diagram). EGFR family ligands include EGF-and EGF-like ligands, transforming growth
factor (TGF)-α and heregulins (HRGs, also known as neuregulins, NRGs). As indicated by the numbers in parentheses beneath the ligands,
each ligand binds preferentially to a particular EGFR family member. HER2, while lacking any known ligand, is the preferred binding
partner of for all EGFR family members. HER3 lacks intrinsic kinase activity due to mutation of critical amino acids in the kinase domain;
therefore, it is inactive on its own or as a homodimer. Transduction of EGFR signals occurs through intracellular adaptor proteins, which
transmit signals through cascades such as the RAS/RAF/MEK/mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3 -kinase
(PI3K)/AKT cascades. The downstream proteins in these signaling cascades can shuttle from the cytoplasm to the nucleus, where they
signal to transcription factors and their complexes such as MYC, ELK, and FOS/JUN. Signal transduction through the EGFR family to
downstream pathways and cascades controls diverse cellular responses such as proliferation, diﬀerentiation, cell motility, and survival as well
as tumorigenesis. Figure adapted from [13]. Abbreviations: PLCγ: Phospholipase Cγ; SHP2: SRC homology phosphatase 2; GAP: GTPase
activating protein; SHC: SRC homology 2 domain and collagen-containing protein; PKC: Protein kinase C; MEK: MAPK/ERK kinase; PAK:
P21-activated kinase; JNKK: JNK kinase; JNK: JUN N-terminal kinase; EGR1: Early growth response protein 1; STAT: Signal transducer and
activator of transcription.
One of the ﬁrst studies implicating the EGFR pathway in
ovarian cancer was the detection of TGF-α in human ovarian
cancer eﬀusions as determined by radioimmunoassay [42].
TGF-α was also shown to increase proliferation as measured
by [ 3H]thymidine incorporation [43]a sw e l la si n c r e a s e
levels of the tumor markers cancer antigen-125 and tissue
polypeptide antigen [44] in EGFR-positive primary human
serous ovarian cancer cells. In the human ovarian adeno-
carcinoma cell line OMC-3, TGF-α induced migration and
invasion as well as gelatinolytic, caseinolytic, and plasmin
activity in a dose-dependent manner [45].
While initial studies suggested that EGF, due to the
inability to detect transcripts in Northern blotting, might
not play a signiﬁcant role in ovarian cancer [43], subsequent
studies indicated that exogenous EGF can also induce eﬀects
associated with transformation. Like TGF-α,t r e a t m e n to f
OMC-3 cells with EGF induced cell migration and invasion
and degradation of extracellular matrix components [45].4 Journal of Oncology
Additionally, human ovarian cancer cell lines treated with
EGF showed signiﬁcant increases in expression of proteins
associated with invasion (urokinase plasminogen activator
anditsreceptor,andplasminogenactivatorinhibitor-1[46]).
EGF can also aﬀect pathways associated with angiogenesis, as
EGF stimulation of the human ovarian adenocarcinoma cell
line OVCAR-3 leads to increased H2O2 levels, which in turn
activates the AKT-P70S6K pathway and increases vascular
endothelial growth factor transcription through hypoxia-
inducible factor-1α expression [47].
While earlier studies focused on EGFR ligands in ovarian
cancer, emerging studies examined the mechanism of EGFR
activation itself. For example, Campiglio et al. detailed the
activation characteristics of the EGFR family members upon
addition of EGF or HRG in human ovarian cancer cell
lines containing diﬀerent levels of EGFR family proteins
[48]. In this report, they show that the pattern of EGFR
family activation in human ovarian cancer cells appears to
be distinct from that of human breast cancer cell lines;
whileEGFRandHER2wereconsistentlyactivateduponEGF
treatment, HER3 and HER4 activation depended upon the
relative abundance of each receptor in ovarian cancer cells.
Additionally, HER3 activation could occur independently of
HER2 [48]. This complex pattern of EGFR family activation
could in part explain the poor rate of response to EGFR
inhibition in ovarian cancer.
Further elucidation of the eﬀects of EGFR signaling in
ovarian cancer comes from inhibition of EGFR in cultured
human ovarian cancer cells. For example, treatment of the
human ovarian serous epithelial cancer cell line OVCA420
with the anti-EGFR murine monoclonal antibody (mAb)
C225 resulted in decreased levels of cell cycle progression-
associated proteins Cyclin-dependent kinase (CDK) 2,
CDK4, and CDK6 and increased expression of the cell cycle-
inhibiting protein P27Kip1, along with increased association
of P27Kip1 with the CDKs [49]. Additionally, modulation of
other cell cycle proteins was observed, including decreased
expression and phosphorylation of the CDK substrates
RB and P130 and decreased protein levels of cyclin A.
Modulation of these proteins upon C225 treatment was
associated with an increase in the proportion of cells in
the G1 phase of the cell cycle. The eﬀects observed upon
EGFR inhibition were enhanced upon combined treatment
of human ovarian cancer cells with the anti-HER2 murine
mAb 4D5 [49].
As transactivation pathways in various cell systems have
been delineated, so have the pathways associated with EGFR
family activation in ovarian cancer. For example, Vacca et al.
have provided evidence that the GPCR ligand, endothelin
(ET)-1, can activate EGFR in the human ovarian cancer
cell line OVCA 433 [50]. ET-1 has been observed to play
a role in mitogenic autocrine loops in various cultured
cell types including human ovarian cancer [51, 52]a n d
is proposed to contribute to tumor growth in vivo [53].
ET-1 treatment increased phosphorylation of EGFR and its
downstreamproteinsSRChomology2domainandcollagen-
containing protein (SHC) and ERK2 as well as increased
SHC-GRB2 association [50]. These eﬀects were reversed
upon pretreatment of OVCA 433 cells with the EGFR
inhibitor tyrphostin AG1478 as well as the ETA-speciﬁc
antagonist BQ-123 [50].
More recent studies have found additional signaling
molecules or pathways that contribute to EGFR-mediated
malignant phenotype in human ovarian cancer cell lines,
includingEGFR-interleukin-6crosstalkthroughJanuskinase
2/Signal transducer and activator of transcription 3 sig-
naling to mediate epithelial-mesenchymal transition [54],
coactivation of Src/EGFR and axin/glycogen synthase kinase
(GSK)-3β pathways and induction of invasion by β-arrestin
activation of the ET-A receptor [55], and Src/EGFR trans-
activation, cyclooxygenase-2 expression, and cell migration
upon LPA2 stimulation in CAOV-3 cells [56].
2.DiseaseModels, Knockouts, and
Assaysfor EGFRinOvarianCancer
In addition to the studies alluded to above in determining
the eﬀects of molecular modulations of EGFR and its
biochemical and biological eﬀects, several other approaches
for studying EGFR have been used; these are summarized in
Table 1. As EGFR is an extracellular signaling protein, the
assays most commonly used in examining EGFR in human
ovarian cancer cell lines or tissues involve methods that
directly or indirectly measure EGFR activity. Assays include
methodsfordetectingincreasedlevelsoftheEGFRgene(e.g.,
ﬂuorescence in situ hybridization) or protein (e.g., immuno-
histochemistry, Western blotting) as well as expression of
activating EGFR mutations (e.g., polymerase chain reaction
+ sequencing) or measurement of EGFR protein activity
(e.g., Western blotting of EGFR phosphorylation sites, in
vitro kinase assays).
To determine the eﬀects of EGFR activation or inhibition
in tumor formation, human ovarian tumor cells are most
frequently implanted heterotopically (subcutaneously) in
immunocompromised mice (Table 1). No reports of “true
orthotopic” implantation such as in the ovarian bursa of
mice have been found in EGFR studies in ovarian cancer,
presumably due to the complex and labor-intensive nature
of these procedures, while a few reports of “semiorthotopic”
implantations via intraperitoneal (IP) injection were identi-
ﬁed. While IP tumor implantation oﬀers a model potentially
more reﬂective of advanced ovarian cancer in the patient
than subcutaneous injection [57], the diﬃculty in measuring
tumor volume in intact mice has precluded its widespread
use in anti-EGFR drug studies.
In addition to implantation of human tissues or cells
via xenografts, animal models utilizing other methods of
tumor formation have been used to study ovarian cancer.
(For comprehensive reviews on animal tumor models, see
[58–61].) Most of these animal models utilize mice, and
the methods used to induce tumor formation include
(1) exposure to radiation (e.g., [62]) or chemicals (car-
cinogens or hormones) introduced at or near the ovary
(e.g., [63]), (2) syngeneic models in which spontaneously
transformed murine ovarian epithelial cells are transplanted
into immunocompetent mice (e.g., [64]), and (3) knockout
or transgenic models in which selected genes are removedJournal of Oncology 5
Table 1: Summary of assays used in detecting EGFR in vitro and in vivo. Aside from high-throughput methods (such as cDNA arrays,
comparative genomic hybridization, and reverse phase protein arrays) and xenograft tumor assays, more broadly encompassing biological
methodssuchasassaysforinvasion,migration,orgeneknockoutshavebeenexcluded.cDNA:complementaryDNA;PCR:polymerasechain
reaction.
EGFR assay method Assay output Performed in ovarian
cancer?
Platform for ovarian
cancer
References for ovarian
cancer
cDNA Array Detection of mRNA
levels of various genes Yes∗ Patient tissue, Human
cell lines [172]
Comparative Genomic
Hybridization
Detection of copy
number changes in
chromosomes
Yes∗ Patient tissue, Human
cell lines [173]
Chromatin
Immunoprecipitation
Detection of stable
protein-DNA
associations
No
Coimmunoprecipitation
+ Western blotting
Detection of stable
protein-protein
associations
No
Crystallography
Determination of entire
structure or portions of
molecule; interacting
molecules
No
Enzyme-linked
Immunosorbent Assay
Determination of
amount of protein in
sample
Yes Patient tissue [174]
Fluorescence/
Chromogenic in situ
Hybridization
Determination of gene
copy number Yes Patient tissue [3, 6, 35, 36]
Flow Cytometry/
Fluorescence-Activated
Cell Sorting
Determination of
protein levels at cell
surface
Yes Patient tissue, Human
cell lines [175–179]
Immuno-
histochemistry/
Immunocyto-chemistry/
Immunoﬂuorescence
(includes Tissue
Microarrays)
Determination of
presence, location, or
amount of protein in
tissue/cell
Yes
Patient tissue, Patient
eﬀusions, Human cell
lines
[4, 5, 35–
37, 40, 41, 43, 46, 97,
117, 123, 178, 180–195]
In vitro Kinase Assay Measurement of
intrinsic kinase activity No
Mass Spectrometry after
Protein Enrichment
/Puriﬁcation (e.g.,
Immunoprecipitation,
Chromatographic
Separation, Baculovirus
Expression)
Detection of protein
modiﬁcation sites (e.g.,
phosphorylation,
glycosylation); changes
in protein levels or
proteomic proﬁles,
protein-protein
complexes
No
Microscopic Techniques
(e.g., Confocal)
Determination of
presence, location, or
a m o u n to fp r o t e i ni nc e l l
No
Mulitplex Antibody
Arrays (Solid Phase or
Bead Based)
Detection of multiple
molecules (usually
proteins) of interest
Yes∗ Patient serum, Human
cell lines [196, 197]
Northern Blotting Determination of
steady-state RNA levels Yes Patient tissue, Human
cell lines [43, 186, 193, 198, 199]
PCR + DNA analysis
(e.g., Sequencing,
Restriction Fragment
Length Polymorphisms,
Denaturing Gradient
Gel Electrophoresis)
Detection of known
mutations/
polymorphisms
Yes Patient tissue, Human
cell lines
[6, 35–
37, 117, 130, 187, 200]6 Journal of Oncology
Table 1: Continued.
EGFR assay method Assay output Performed in ovarian
cancer?
Platform for ovarian
cancer
References for ovarian
cancer
Quantitative PCR Measurement of RNA
levels of interest Yes Human cell lines [39, 174, 201]
Radioligand Binding/
Radioimmunoassay
Estimation of number of
receptors; determination
of ligand or agonist/
antagonist binding
kinetics
Yes
Patient tissue, Patient
eﬀusions, Human cell
lines
[42–45, 199]
Reverse Phase Protein
Array
Determination of levels
of several proteins and
protein modiﬁcations of
interest
Yes Patient tissue, Patient
eﬀusions [202, 203]
Reverse
Transcription-PCR +
Southern Blotting
Determination of
mRNA levels Yes Human cell lines, Rat
cell lines [198, 204]
Southern Blotting Detection of gene of
interest Yes Rat cell lines [198]
Tryptic Digests +
Peptide Resolution (e.g.,
Reverse Phase High
Performance Liquid
Chromatography)
Determination of
phosphorylation sites of
protein
No
Western Blotting
Determination of
protein abundance,
protein-associated
modiﬁcations (e.g.,
phosphorylation,
cleavage, ubiquitination)
Yes Patient tissue, Human
cell lines
[38, 39, 46, 48–
50, 56, 147, 175, 177,
178, 181, 186, 196, 200,
201, 204–212]
Xenograft Tumors
Determination of eﬀect
of gene/cell perturbation
on tumor growth
Yes Human and mouse cell
lines
[47, 49, 147, 178, 213–
219]
∗EGFR was detected and reported, but samples were not necessarily preselected for alteration of EGFR sequence, expression, or activity.
or activated within the mouse. While none of these methods
have directly examined the role of EGFR aberrations in ovar-
ian cancer, some of these methods have been applied to other
tumor models (e.g., glioma [65], lung adenocarcinoma [66])
in which EGFR perturbations (activating mutations) have
been studied, indicating that EGFR-mediated tumor devel-
opment can be successfully developed in transgenic mice.
In one study where signaling proteins downstream of
EGFR induced ovarian cancer, transgenic mice harboring
exogenously controllable (“ﬂoxed”) expression of phos-
phatase and tensin homolog (PTEN) and mutated K-RAS
genes were induced to gain oncogenic K-RAS and lose
tumor suppressing PTEN expression in the ovaries via
injection of an adenovirus-Cre recombinase vector into the
infundibulum [67]. All animals developed endometrioid
adenocarcinoma of the ovary and, unlike previous ovarian
tumor models, were well diﬀerentiated, reﬂecting similar
histomorphology to human epithelial ovarian cancers. Thus,
this model allows for detailed study of the endometrioid
subtype of epithelial ovarian cancer at various stages of
tumor development and with some manipulations could be
used to study the eﬀects of EGFR aberrations in ovarian
tumor development. Mouse models for other subtypes of
epithelial ovarian cancers (serous, mucinous, clear cell,
transitional) await further development.
3.TargetingEGFRinOvarianCancer
While several strategies have been attempted to block
EGFR activity, two types of inhibitors are currently used
in the clinic: (1) monoclonal antibodies (mAbs), and (2)
small molecule tyrosine kinase inhibitors (see [68, 69]f o r
reviews). A summary of these inhibitors and their uses in
clinical trials is shown in Table 2. While the various natural
functions of antibodies may contribute to their utility as
anticancer agents, including their role as modulators or
eﬀectors of the immune response, molecular carriers, and
pharmacologic agents that directly interfere with activation
of the receptor and its downstream pathways (reviewed in
[70]), the focus of this paper will be on mAbs as pharma-
cologic agents. As indicated above by the in vitro studies
in human ovarian cancer cells, EGFR and its downstream
eﬀectors may be activated directly or indirectly by numerous
other signaling molecules. Since determination of which
molecules are key to EGFR signaling in ovarian cancers isJournal of Oncology 7
not completely understood, the focus will be on inhibition
of EGFR and its family members.
3.1. Anti-EGFR Monoclonal Antibodies. Anti-EGFR mAbs
that are used in the clinic typically bind to the extracellular
domain of EGFR (e.g., [71, 72]). While there are potentially
many diﬀerent mechanisms of inhibition, in many of the
known cases, the antibodies prevent ligand binding (in
the case of wild-type EGFR), promote antibody-receptor
complex internalization [73–75], induce transient decrease
of EGFR expression [76], inhibit EGFR heterodimerization
[72, 77, 78], and increase ubiquitin-mediated degradation
[79]. The downstream eﬀects of inhibition in EGFR-
dependent cancer cells include decreased TGF-α secretion,
angiogenesis, cell migration, invasion (reviewed in [80]),
and induction of apoptosis [81]. Additionally, certain engi-
neered IgG subclass antibodies in which the Fc region is
maintained can induce antibody-dependent cell-mediated
cytotoxicity or complement activation (see [82, 83]f o r
comprehensive reviews). To reduce the likelihood of patient
immune response against the therapeutic antibody, mouse
mAbs have been humanized (reviewed in [84]); these are
reﬂected by their antibody names. For example, human-
mouse chimeric antibodies of 30% mouse composition
are designated as “-ximab” (e.g., cetuximab); humanized
antibodies with 10% mouse composition are given the “-
zumab” designation (e.g., trastuzumab, matuzumab), while
fully humanized antibodies are designated as “-mumab”
(e.g., panitumumab).
Cetuximab (Erbitux) was the ﬁrst anti-EGFR mAb
tested in the clinic. Cetuximab inhibits growth of a variety
of cultured cancer cells including breast, prostate, lung,
colon, kidney, head and neck (reviewed in [85]), pancreas
[86], and bladder [87] and can induce regression (either
alone or as a combined therapy) of a number of human
tumor xenografts such as epidermoid carcinoma [88], renal
cell carcinoma [89], pancreatic cancer [86, 90], non-small
cell lung cancer (NSCLC) [91], thyroid carcinoma [92],
and glioblastoma multiforme [93]. Cetuximab demonstrates
activity in patients with colorectal, head and neck, and lung
cancers [94, 95].
Reports for cetuximab in ovarian cancers have appeared
recently (Table 2), including its use as a single agent in a
p h a s eI It r i a l[ 96] and in two other phase II trials in combi-
nation with carboplatin with or without paclitaxel (Taxol)
[97, 98]. In all studies, EGFR positivity was determined
by immunohistochemistry (IHC) and in two cases was
used among the criteria for inclusion [96, 98]. Cetuximab
therapy alone showed 4% (1/25 patients) partial response
(PR) [96], while the cetuximab + carboplatin trial showed
12% (3/26 patients) complete response (CR) and 23% (6/26
patients)PR[97].Whilenoresponseratewasreportedinthe
cetuximab + carboplatin + paclitaxel trial, progression-free
survival(PFS)at18monthswas39%,whichdidnotmeetthe
authors’ criteria for meaningful response [98] and did not
proceed to the next phase of accrual. There was no evidence
of correlation between EGFR levels and patient response in
any of the reports. The implications of these and subsequent
results will be discussed in the “Next frontiers” section.
Among other anti-EGFR antibodies, a single multi-
institution open-label phase II trial was reported in patients
with ovarian cancer using matuzumab (EMD 72000) [99].
WhilescreeningforthisphaseIItrialincludedEGFRpositiv-
ity in the ovarian tumor as determined by IHC, no responses
to therapy were observed. To date there are no approved
anti-EGFR antibodies for ovarian cancer, and while there
was one clinical trial involving panitumumab (Vectibix) in
combination with AMG 706 and gemcitabine-cisplatin in
patients with advanced cancers (including ovarian), this trial
wasterminated.Currently,therearenofullreportsofclinical
trials for ovarian cancer with other anti-EGFR antibodies
such as zalutumumab (HuMax-EGFr) and nimotuzumab
(BIOMAb
EGFR). Among patented mAbs directed towards
EGFR that are not yet in clinical use, one has been proposed
for use in ovarian cancer (patent number WO2005010151);
however, as it is directed against deletion mutants of EGFR
(particularly EGFRvIII), its use in ovarian cancer is likely to
be limited.
Due to potential EGFR transactivation by other EGFR
family members, mAbs targeting other EGFR family mem-
bers have also been tested or used clinically against various
cancer types such as breast and urothelial malignancies
(reviewed in [100]). This includes clinical trials targeting
HER2 such as a phase II multi-institutional trial in ovarian
cancerinwhichtrastuzumab(Herceptin)wasusedasasingle
agent in patients determined HER2 positive by IHC [101].
An overall response rate of 7.3% (1 CR, 2 PR) was reported.
However, the relatively low frequency of HER2 ampliﬁcation
in unselected ovarian cancers (e.g., 10%–23%; [35, 102]) has
precluded more extensive studies. Pertuzumab (Omnitarg),
a HER2 dimerization inhibitor, was administered with
gemcitabine (Gemzar) in platinum-resistant ovarian cancer
patients in a phase II safety study [103]; eﬃcacy awaits
further reports.
Among antibodies targeted toward other signaling
molecules known to activate EGFR are monoclonals for IGF-
1R, including 19D12 and EM164. These antibodies have
beendemonstratedtoinhibitproliferationofhumanovarian
cancercells[104]aswellastumorgrowthinmousex enograft
studies [105]. However, whether EGFR aberrations aﬀect
responsetoanti-IGF-1Rtreatmentorwhetherinhibitioncan
be enhanced by anti-EGFR treatment is unknown.
3.2. Small Molecule EGFR Inhibitors. Small molecule inhibi-
tors, based on modeling by structure-based drug design
[106] or by screening (e.g., erlotinib, [107]), appear to
act intracellularly by competing with ATP binding in the
catalytic region of the kinase domain, thereby abrogat-
ing enzymatic activity of the kinase and its subsequent
downstream signaling eﬀects (reviewed in [108]). Small
molecule inhibitors directed against EGFR generally prevent
homo- and heterodimerization between it and other EGFR
family members; however, in some cases the inhibitor allows
heterodimerization but prevents activation of these dimers
[109]. While most mAbs are designed to target full length
EGFR, many small molecule inhibitors can target mutant
RTKs such as EGFRvIII that lack a critical extracellular
regulatory region targeted by some of the antibodies. Small8 Journal of Oncology
Table 2: Summary of clinical trials using EGFR inhibitors in ovarian cancers References are in parentheses next to the ﬁrst author of the study.
CT: clinical trial; IHC: immunohistochemistry; RPPA: reverse phase protein array; CR: complete response; PR: partial response; SD: stable
disease; pt: patient; PFS: progressionfree survival; GOG: Gynecologic Oncology Group; VEGFR:vascular endothelial growth factor receptor.
(a) Monoclonal Antibodies
Study and Year CT no. Phase # Pts Therapy Selection criteria Outcome Comments
Secord et al.
2008 [97]
NCT
00086892 II 28 Cetuximab +
Carboplatin
Recurrent, platinum-sensitive
disease
CR: 3 pts Response rate criteria not met for
next stage of accrual. 26 pts were
EGFR positive by IHC.
PR: 6 pts
SD: 8 pts
Konner et al.
2008 [98]
NCT
00063401 II 40
Cetuximab +
Paclitaxel +
Carboplatin
Grade III-IV debulked tumor,
EGFR positive by IHC
Median PFS:
14.4 months
Combination was adequately
tolerated. No increase in PFS when
compared to historical data. PFS at 18
months:
39%
Schilder et al.
2009 [96] II 25 Cetuximab
Persistent or recurrent ovarian
or primary peritoneal disease,
EGFR positive tumors by IHC
12 serologic markers examined
before and during treatment. No
correlation between PFS and
marker changes, but high baseline
of markers associated with earlier
disease progression.
PR: 1 pt
SD: 9 pts
Seiden et al.
2007 [99]
NCT
00073541 II 37 Matuzumab Recurrent platinum-refractory
disease, EGFR positivity by IHC
No objective
response
Primary objective was
pharmacodynamic; signal
transduction evaluation. 75 pts
were screened for EGFR status.
SD:
16%–22%
Bookman et al.
2003 [101]
GOG-160 II 41 Trastuzumab Persistent and/or refractory
disease with 2-3+ HER2 by IHC
CR: 1 pt Serum HER2 levels not associated
with clinical outcome. PR: 2 pts
(b) Small Molecule Inhibitors
Study and YearCT no. Phase # Pts Therapy Selection criteria Outcome Comments
Posadas et al.
2007 [203]
NCT
00049556 II 24 Geﬁtinib Platinum-refractory disease
No objective
response
Protein correlates done with RPPA.
No signiﬁcant correlation between
EGFR phosphorylation and tumor
response
SD: 37% for
>2m o n t h s
Schilder et al.
2005 [112]
NCT
00023699 II 27 Geﬁtinib Persistent or recurrent disease PR: 1 pt
Analyses suggest trend towards
responsiveness in EGFR positive (by
IHC) pts. Activating mutations
documented in the PR pt.
Wagner et al.
2007 [115]
NCT
00189358 II 56 Geﬁtinib +
Tamoxifen
Disease refractory or resistant to
platinum-taxane-based therapy
No objective
response EGFR positivity not a prerequisite;
EGFR status not determined
SD: 16 pts
Gordon et al.
2005 [116] II 34 Erlotinib Relapsed or progressive disease,
EGFR positivity by IHC
PR: 2 pts Primary goal was to estimate the
objective tumor response rate to
erlotinib as a single agent.
SD: 15 pts
Vasey et al.
2008 [118] Ib 45
Erlotinib +
Docetaxel +
Carboplatin
Chemona¨ ıve pts
CR: 5 pts Phase Ib dose ﬁnding study.
Addition of erlotinib to other agents
did not increase response rate.
PR: 7 pts
(23
evaluable)Journal of Oncology 9
(b) Continued.
Study and YearCT no. Phase # Pts Therapy Selection criteria Outcome Comments
Nimeiri et al.
2008 [117]
NCT
00126542 II 13 Erlotinib +
Bevacizumab
Recurrent or refractory disease,
≤2 prior cytotoxic
chemotherapies; no previous
anti-EGFR or VEGFR therapies
No indication of improvement over
bevacizumab treatment only. No
EGFR mutations detected; one
EGFR 2+ IHC staining detected.
CR: 1 pt
PR: 1 pt
Kimball et al.
2008 [122]
NCT
00317434 I1 1 Lapatinib +
Carboplatin
Recurrent, platinum-sensitive
disease
PR: 3 pts No screening or measurement of
EGFR or HER2 performed. SD: 3 pts
Campos et al.
2005 [123]
II 105 CI-1033 Relapsed or refractory disease
No objective
response
Baseline HER1-2 levels determined
by IHC. No association between
HER levels and SD. SD: 26–34%
molecule inhibitors can bind reversibly (e.g., geﬁtinib or
erlotinib)orirreversibly(e.g.,CI-1033)toEGFR.Theclinical
signiﬁcance of these diﬀerent mechanisms of inhibition is
not yet known.
Geﬁtinib (Iressa or ZD1839), which inhibits a variety
of cancer cell lines and xenograft tumors (reviewed in
[110]), including ovarian [111], was tested as a single agent
in two trials [112, 113]. In both trials, EGFR aberrations
were not included as selection criteria but were assayed
via IHC for EGFR protein expression [112]o rv i ar e v e r s e
phase protein array (RPPA) for total and phospho-EGFR
levels [113]a sw e l la sf o rEGFR mutations in exons 18–
21 via polymerase chain reaction (PCR) ampliﬁcation and
nucleotide sequencing [112]. In both studies, there was no
CR; 0%–4% had PR, and 4%–37% had stable disease (SD)
[112, 113]. While decreased EGFR phosphorylation and
expression, as determined by RPPA, was observed in >50%
of geﬁtinib-treated patients, this was not associated with
clinical beneﬁt or response [113]. However, EGFR positivity
via IHC was associated with longer PFS [112]. Additionally,
a mutation in exon 19 was detected in the one partially
responding patient [112], a location that was shown to be
responsive to geﬁtinib treatment in NSCLC patients [114].
Geﬁtinib was also used in combination with tamoxifen
in a phase II study in Germany involving patients refrac-
tory or resistant to platinum-taxane-based treatment but
not prescreened for estrogen receptor or EGFR expression
[115]. While this combination therapy was well toler-
ated, it was reported to be ineﬀective against platinum
refractory/resistant ovarian cancer as there were no tumor
responses.
Another small molecule inhibitor, erlotinib (Tarceva),
demonstrated limited activity for ovarian cancer patients in
a multicenter phase II trial, with only 2 chemorefractory
patients in 34 demonstrating a partial response to treatment
[116]. While EGFR expression was determined by IHC, low
expressionwasnotusedasacriterionforexclusion.Erlotinib
has also been tested in combination with other chemothera-
peutic agents, including the antivascular endothelial growth
factor (VEGF) antibody bevacizumab (Avastin) in a phase
II trial [117], and docetaxel (Taxotere) with carboplatin in a
phase Ib trial [118]. EGFR aberration or positivity was not
an inclusion criterion in either study, and EGFR status was
reported in only one study [117], which examined EGFR
positivity via IHC and activating mutations in exons 19
and 21 via PCR ampliﬁcation and sequencing. The objective
response rates were 15% (2/13 patients) for the erlotinib +
bevacizumab therapy [117] and 52% (12/23 patients) for
erlotinib + docetaxel + carboplatin [118]. No EGFR muta-
tions were detected, and one patient demonstrated EGFR
positivity, but this patient was unresponsive to erlotinib +
bevacizumab therapy [117]. Due to lack of improvement
over bevacizumab therapy alone and two incidents of fatal
gastric perforations, the erlotinib + bevacizumab study
was discontinued [117]. Whether these are due to the
combinatorial eﬀects of the drugs or due to bevacizumab
alone, which has been reported to induce gastric perforation
[119], remains undetermined. The response rate of the
erlotinib+docetaxel+carboplatintherapywasslightlylower
than that of a docetaxel + carboplatin therapy previously
conducted by the same group (52% versus 59%, [118, 120]),
butduetogoodpatienttoleranceofthe3-drugcombination,
it was recommended for further studies, particularly as
maintenance therapy.
Lapatinib(Tykerb,Tyverb),adualEGFR-HER2inhibitor
[121],wastestedinamulticenterphaseItrialincombination
with carboplatin in patients with platinum-sensitive recur-
rent ovarian cancer [122]. Patients were not prescreened or
measured for EGFR in this study. Three of 11 patients (27%)
had PR, and 3 patients (27%) had SD [122]. This treatment
regimen was not recommended, as it had a low response
rate and signiﬁcant treatment toxicities, including grade 3–
4 neutropenia and grade 4 thrombocytopenia. In addition,
2 other patients had treatment delays due to development
of nondose limiting grade 3 neutropenia using the initial
combination therapy regimen [122].
The irreversible pan-EGFR family inhibitor CI-1033
(Canertinib) was administered in a multicenter open-label
phase II trial for ovarian cancer patients who had failed
prior platinum-based therapy [123]. While baseline EGFR
family levels were determined via IHC from archival patient
tumor specimens, it was not used as a selection criterion.10 Journal of Oncology
No objective response was observed, although SD was
conﬁrmed in 26%–34% of the patients (depending on the
dosage). There was no association between EGFR family
levels by IHC and stable disease.
Due to the relatively unremarkable results of anti-EGFR
small molecules in earlier clinical trials, more recent trials
have focused on small molecules that bind irreversibly or
haveabroadertargetrange.Forinstance,BIBW2992(Tovok)
binds irreversibly to EGFR and HER2 and can inhibit both
wild type EGFR and activated mutants of EGFR and HER2
[124]. BIBW2992 was shown to inhibit growth of human
NSCLC cells implanted in nude mice more eﬀectively than
erlotinib [124]. Several phase I and II trials are underway
with BIBW2992 as a single agent or in combination with
various agents such as paclitaxel, cisplatin, or temozolomide
(Temodar, Temodal) in patient groups consisting of various
solid tumors including glioma, NSCLC, prostate, breast,
and colorectal cancer (http://www.clinicaltrials.gov/). A few
trials will screen patients for EGFR or HER2 status, whether
by detection of gene ampliﬁcation or by activating EGFR
mutations. An example of a small molecule with an even
broader target range is AEE788, which inhibits EGFR, HER2,
and vascular endothelial growth factor receptor (VEGFR)
[125]. While the current focus of AEE788 is on glioblastoma,
there is also a study that assesses the safety and clinical
activityofAEE788invarioussolidtumors.Thereiscurrently
no complete report indicating which tumor types were
included, patient response, and follow up. Other small
molecule EGFR family inhibitors undergoing clinical trials
against solid tumors of various types (speciﬁc types not yet
reported) include HKI-272 and EKB-569.
In lung cancers, sensitivity to EGFR inhibition by small
molecules such as geﬁtinib and erlotinib is associated with
EGFRmutation[126–129].Therefore,Lacroixet al.analyzed
EGFR sequences from exons 18–24 in 18 advanced epithelial
ovarian carcinoma specimens from patients that displayed
objective response or disease stabilization to carboplatin-
paclitaxel-geﬁtinib treatment, along with NSCLC [130].
While 2 of 20 NSCLC samples displayed an activating
deletion in exon 19 (consistent with previous reports), no
EGFR mutations were detected in the ovarian carcinomas.
However, the potential role of mutations, insertions, or
deletions elsewhere in EGFR or other EGFR family members
was not explored.
4. Next FrontiersinAnti-EGFRDrugDiscovery
4.1. Improving Response to EGFR Inhibitors in Ovarian Can-
cer. As detailed by the list of clinical trials, the use of EGFR
inhibitors as single agents or in early combination studies in
ovarian cancer has met with limited success. The regimens
have included EGFR-selective or less selective inhibitors
and administration as single agents or in combination with
other non-EGFR antineoplastic agents. One not yet widely
explored possibility is whether using a combination of an
externally targeting EGFR drug (i.e., mAb) with an internally
targeting drug (i.e., small molecule kinase inhibitor) would
produce better results. So far, there is one complete report
of a phase I study that has determined optimal doses
of combined cetuximab and geﬁtinib therapy in patients
with advanced or metastatic NSCLC previously treated with
platinum therapy [131]. These patients had no detectable
EGFR ampliﬁcations or K-RAS mutations. The regimen,
with the exception of the development of hypomagnesemia,
waswelltolerated.Therewasnoobjectiveresponse;however,
4 of 13 had SD. Based on these results, the group has
recommended an optimum tolerated dose to use in a phase
II trial.
While later studies selected patients based on EGFR
positivity or overexpression via IHC, many of these trials still
demonstrated low eﬃcacy, suggesting that other methods
of EGFR detection might be better suited for pre-drug
screening. Quantitative approaches to assess protein level,
RNA levels, gene ampliﬁcation, and mutations might prove
less subjective and more robust than IHC and could be
included as one of the predictors of patient response. In lung
cancer, gene copy number assessed by ﬂuorescence in situ
hybridization (FISH) has been reported to indicate sensitiv-
ity to EGFR inhibition (reviewed in [132]). Whether EGFR
ampliﬁcation as determined by FISH is a reliable indicator
of EGFR inhibitor sensitivity for other types of cancers has
not yet been conclusively assessed. Additionally, it is possible
that gene increase is associated with mutational activation
of EGFR, serving as a surrogate marker for mutation, and
would suggest that screening by FISH might be limited to
cancers in which EGFR is frequently mutated. At any rate,
clinicaltrialsinwhichbetter-deﬁnedmeasurementsofEGFR
status are taken into consideration have been emerging, such
as screening of EGFR mutations in NSCLC patients prior to
administration of erlotinib.
An understanding of the mechanisms leading to resis-
tance of EGFR inhibitors could help enrich for patients
likely to respond to therapy and more importantly identify
rational combinatorial therapy. Resistance of tumors to
anti-EGFR therapies has been discussed in a number of
reviews (e.g., [133]). Furthermore, various mechanisms of
chemoresistance in tumor treatment have been described
(e.g., see [134, 135]). Resistance can be apparent from
the onset of treatment (“intrinsic”) or develop over time
(“acquired”). While resistance at the physiologic level has
been attributed to mechanisms such as suboptimal immune
system activity or rapid metabolism or poor absorption of
thedrug,resistanceatthemolecularlevelhasbeenattributed
to expression or activation of molecules or signaling path-
ways that can directly or indirectly override the eﬀects of
the drug (reviewed in [136]). This activation may occur via
intracellular or intercellular mechanisms, and the activating
intercellular source could either be another tumor cell or be
the surrounding stroma (reviewed in [137]).
Anti-EGFR therapy resistance mechanisms include pro-
duction of EGFR-activating ligands, receptor mutations,
constitutive activation of downstream pathways, and acti-
vation of alternative signaling pathways (reviewed in
[138, 139]). Another mechanism recently suggested is
increased resistance to autophagic cell death upon increased
EGFR expression via stabilization of the facilitated glucose
transporter sodium/glucose cotransporter 1 (SGLT1) [140].
SGLT1 can transport glucose “upstream” of a glucoseJournal of Oncology 11
gradient, enabling cells to accumulate higher glucose con-
centrations than their environment, as in the case of cancer
cells, and providing more “food” for the cell [141]. Increased
SGLT1 stability is dependent on EGFR expression and not its
activity [140]. Thus, agents that target EGFR activity but not
its expression are likely ineﬀective.
Another potential mechanism of EGFR inhibitor resis-
tanceisinﬂammation,suchasbyreleaseoftheinﬂammatory
cytokine prostaglandin E2, which in lung cancer cells
induced phosphorylation of MAPK, indicating a bypass of
EGFR activation (reviewed in [142]). One other consider-
ation regarding chemoresistance is the sequence or timing
of multidrug administration. Proliferation of an esophageal
squamous epithelial cancer cell line possessing autocrine
EGFR activity was either inhibited or enhanced depending
on whether a cytotoxic drug (platinum derivative or taxane)
was administered before or after an EGFR inhibitor [143].
While many of these mechanisms have been studied in
other cancer types, the data for ovarian cancer is currently
sparse.
Experimental results have also indicated the need to
better understand the interaction of EGFR with other family
members, signaling events, and the tumor environment in
ovarian as well as in other cancers. As noted earlier, relative
diﬀerences in levels of EGFR family members induced
diﬀerent dimerization partners upon stimulation by a given
ligand in ovarian cancer cell lines [48]. Further, there is
evidencethatHER3,afamilymemberalsopresentinovarian
cancers and associated with increased tumor aggressiveness
[144]andpoorprognosis[145],playsacriticalroleinEGFR-
and HER2-driven tumors (reviewed in [146]). Therefore,
only targeting EGFR will likely be insuﬃcient due to
functional overlap by other EGFR family members. Also, in
mouse studies using SU11925, a small molecule that targeted
both EGFR and HER2, a higher concentration of SU11925
was required to inhibit HER2 phosphorylation in xenograft
tumorsthaninculturedhumanormurinecellswhenrelative
HER2 levels in the cell were higher than EGFR [147]. These
results point to a potential shortcoming of small molecule
inhibitors in vivo.
As evident here and in numerous other reports on
EGFR inhibitors in various cancer cell types, other signaling
molecules aﬀected by or eﬀecting EGFR family members
will have to be concomitantly examined in solid tumors.
First, signaling of the EGFR family occurs primarily in
trans with HER2 being the preferred binding partner [14].
Also, in human breast cancer cells, there is evidence that
cells can escape geﬁtinib treatment due to increased HER3
expression induced by AKT-mediated negative feedback
signaling [148]. Additionally, examining signaling proteins
further downstream indicates that constitutive activation of
these pathways must also be taken into consideration. For
example, EGFR-overexpressing human cell lines treated with
geﬁtinib were resistant when PTEN, the negative regulator
of the PI3K/AKT pathway, was not functional [149, 150]. In
NSCLC, 0 of 8 patients with both EGFR ampliﬁcation and
K-RASmutation responded to erlotinib treatmentcompared
to 4 of 5 responders with EGFR ampliﬁcation alone [151].
Further, tumors with RAS mutations in several cell lineages
such as NSCLC, colon, and bronchioalveolar carcinoma
are resistant to anti-EGFR receptor agents and may have a
worsened outcome with therapy [151–153]. This is leading
to widespread testing of RAS mutations in patients (such
as the recent study in ovarian cancer [154]) and, indeed, is
approved by the European Medicines Agency as an exclusion
criterion for anti-EGFR therapy in colorectal cancer in
Europe. Optimal eﬃcacy of anti-EGFR therapy is likely to
requireconcurrenttargetingofthePI3K/AKTorRAS/MAPK
pathways in patients with mutational activation of these
downstream components. To this end, trials that target both
EGFR and the PI3K/AKT pathway have been performed
or are underway, including cancers for glial cells and head
and neck. While new agents that target the PI3K/AKT
pathway, including XL765 or XL147, are being tested against
various solid tumors in combination with erlotinib, no
known combination trials exist in ovarian cancer. Also, while
trials utilizing the farnesyl transferase inhibitor lonafarnib
(Sarasar), which targets RAS [155], are underway, none are
currently examining the combination of EGFR and RAS
inhibition in any tumor type.
In addition to signaling across EGFR family members
and proteins downstream, consideration of other trans-
membrane signaling molecules must be taken into account.
Considerable data in various cell types including hepatoma
[156], prostate [21], and breast [157] has shown that
EGFR inhibition can be overridden by IGFR stimulation.
Moreover, there is in vitro evidence in human NSCLC
and head and neck squamous cell cancer cells to support
therapies combining EGFR and GPCR inhibitors, such as
antagonists for bradykinin (CU201) or gastrin (PD176252)
(e.g., [158, 159]). Recently, ampliﬁcation of the RTK gene
MET has been shown to bypass EGFR receptor inhibition
in human lung cancer cells and was present in 4 of 18
lung cancer specimens that developed resistance to geﬁtinib
or erlotinib, supporting the idea that MET should also be
targeted in EGFR-dependent cancers [160]. On the other
hand, treatment of solid tumors with the dual EGFR-
VEGFR inhibitor vandatanib (ZD6474 or Zactima) was
ineﬀective [161]. Based on these reports and the emergence
of numerous potential EGFR-mediated signaling proteins
of interest in ovarian cancers, determination of which
proteins play crucial roles in ovarian tumors might prove
to be a challenging process. High-throughput methods
such as gene expression arrays and RPPA should help in
determining which genes and proteins are modulated upon
single and combination treatment of ovarian cancer cell
lines and tissues. For example, Skvortsov et al. have used
2-dimensional gel electrophoresis and mass spectrometry
to identify proteins associated with sensitivity or resistance
to C225 in two colon cancer cell lines [162]. Additionally,
development of robust algorithms to predict eﬀective drug
combinations (e.g., [163]) should aid in streamlining high-
throughput studies and increase the likelihood of ﬁnding
successful combinations.
Despite these challenges, reports utilizing adherent
human epithelial cancer cell lines and tumor types suggest
that mechanisms of resistance and methods to overcome
resistance could be determined and incorporated into12 Journal of Oncology
ovarian cancer therapies. For instance, MAPK phospho-
rylation was not inhibited in an EGFR-positive, geﬁtinib-
resistant human bladder cancer cell line upon geﬁtinib
treatment, while MAPK phosphorylation decreased in an
EGFR-positive, geﬁtinib-sensitive cell line [164]. Moreover,
in the geﬁtinib-sensitive cell line, increased GSK-3β activity
and decreased cyclin D1 levels were observed upon geﬁtinib
treatment and correlated with responsiveness. Additionally,
platelet-derived growth factor receptor-β (PDGFR-β)w a s
observed to short circuit the EGFR/MAPK pathway in the
geﬁtinib-resistant cells [164]. These results suggest that, in
bladder cancer, MAPK kinase phosphorylation could be a
marker for resistance while GSK-3β activation or cyclin
D1 levels could be a marker for sensitivity of EGFR drug
treatment, and that inhibition of both EGFR and PDGFR-
β w o u l db em o r ee ﬀective in treatment of EGFR-positive
bladder cancers than EGFR alone.
4.2. Improving Understanding of EGFR Processes in Ovarian
Cancer. With the emergence of high-throughput technolo-
gies and their accompanying development and reﬁnement of
data analyses, reports contributing to further understanding
of ovarian cancers have emerged. Among the ﬁrst reports
utilizing gene arrays was that of Wang et al., who identiﬁed
geneticdiﬀerencesbetweenhumanovariantumorspecimens
(comprising 5 diﬀerent histopathologic types) and normal
ovarian tissue [165]. Later studies expanded the number
and reﬁned the analyses of histopathologic types of samples
(serous papillary, clear cell, endometrioid, undiﬀerentiated,
and adenocarcinomas) included in the analyses (e.g., [166]),
as well as compared drug (primarily platinum) sensitive
and resistant samples [167]. While the number of samples
analyzed in depth is increasing, this number is still relatively
small; whether the proﬁle of EGFR-positive ovarian cancers
is diﬀerent from that of other prominent molecular markers
is unknown. Moreover, the most comprehensive proﬁles
characterized thus far have focused on gene alterations,
via comparative genomic hybridization or gene microarrays
(reviewed in [168, 169]), which provide an incomplete
proﬁle of ovarian cancer cells, particularly in the case
of protein signaling-dependent alterations such as EGFR
activation. Thus, more information derived from proteomic
studies is needed.
Based on the current outcomes of EGFR targeted ther-
apy in ovarian cancers, it is evident that patients should
be screened for EGFR status including ampliﬁcation and
mutation; additionally, screening for other EGFR family
members and key downstream eﬀector proteins such as RAS
and PTEN would be preferable. Also, while EGFR in ovarian
cancers has been screened for potential activating events via
presence of EGFRvIII [38, 39] or activating mutations in the
kinase domain [6, 35–37], it is possible that ovarian cancers
might have a yet unidentiﬁed EGFR activating “hot spot.”
Screening and analysis of full-length EGFR will be required
to determine if this is the case.
Determination of other molecular markers for likely
responders or nonresponders toward anti-EGFR therapies
should also be performed; identiﬁcation of such markers
could be facilitated by high-throughput methods that can be
correlated with patient response. High-throughput methods
could also be used to aid in developing predictive models
of drug combination in patients, such as by testing well-
deﬁned chemotherapeutic drugs in a large number of cancer
cell lines and performing cell “population studies,” to better
correlate drug response with precisely deﬁned oncogene
status (e.g., speciﬁc mutations, gene ampliﬁcation), such as
with EGFR [170]. Further studies of other proteins aﬀecting
or aﬀected by EGFR activity, some of which have been
discussed above, should also be performed to clarify their
roles in ovarian cancer, both independently and in context
with EGFR activation. Further, the role of EGFR in diﬀerent
ovarian cancer histotypes should be examined. Additionally,
preclinical combination therapy reports such as by Morelli et
al. [143] suggest that more studies should be performed on
determining proper scheduling of multiple therapies as well
as examination of previously untested drug combinations.
Also of great beneﬁt is designing more streamlined and
rational methods for performing drug combination studies,
such as by development of search algorithms to determine
optimal doses of combined drugs [171].
5. Conclusion
EGFR and its family members play a variety of roles in
oncogenesis and tumor progression in diﬀerent cancer and
cell types. To date, clinical studies using EGFR antagonists in
ovarian cancer have shown limited eﬃcacy. As we learn more
about the complexities of speciﬁc signaling changes associ-
ated with EGFR mutation and overexpression, future studies
using EGFR antagonists in ovarian cancer should focus on
determining reliable predictors for patient responsiveness to
anti-EGFR therapy such as by obtaining good biomarker
proﬁles and utilizing assays most appropriate to determine
EGFR status as well as developing rational combination ther-
apies with EGFR inhibitors. These determinations should be
facilitated by the use of high-throughput methods, as well
as development of robust algorithms to help design experi-
ments and analyze results. Continuing these studies in ovar-
ian and other types of cancers will increase our likelihood of
achieving success in targeting EGFR-dependent tumors.
References
[1] M. H. Roh, D. Kindelberger, and C. P. Crum, “Serous tubal
intraepithelial carcinoma and the dominant ovarian mass:
clues to serous tumor origin?” American Journal of Surgical
Pathology, vol. 33, no. 3, pp. 376–383, 2009.
[2] K. M. Feeley and M. Wells, “Precursor lesions of ovarian
epithelial malignancy,” Histopathology, vol. 38, no. 2, pp. 87–
95, 2001.
[3] I. Dimova, B. Zaharieva, S. Raitcheva, R. Dimitrov, N.
Doganov, and D. Toncheva, “Tissue microarray analysis of
EGFR and erbB2 copy number changes in ovarian tumors,”
International Journal of Gynecological Cancer, vol. 16, no. 1,
pp. 145–151, 2006.
[4] C.-K. Lin, T.-K. Chao, C.-P. Yu, M.-H. Yu, and J.-S. Jin, “The
expression of six biomarkers in the four most common ovar-
iancancers:correlationwithclinicopathologicalparameters,”
APMIS, vol. 117, no. 3, pp. 162–175, 2009.Journal of Oncology 13
[5] H.Brustmann,“Epidermalgrowthfactorreceptorexpression
inserousovariancarcinoma:animmunohistochemicalstudy
with galectin-3 and cyclin D1 and outcome,” International
JournalofGynecologicalPathology,vol.27,no.3,pp.380–389,
2008.
[6] H. Lassus, H. Sihto, A. Leminen, et al., “Gene ampliﬁcation,
mutation, and protein expression of EGFR and mutations of
ERBB2 in serous ovarian carcinoma,” J o u r n a lo fM o l e c u l a r
Medicine, vol. 84, no. 8, pp. 671–681, 2006.
[7] N. J. Maihle, A. T. Baron, B. A. Barrette, et al., “EGF/ErbB
receptor family in ovarian cancer,” Cancer Treatment and
Research, vol. 107, pp. 247–258, 2002.
[8] Y. Yarden and A. Ullrich, “Growth factor receptor tyrosine
kinases,”AnnualReviewofBiochemistry,vol.57,pp.443–478,
1988.
[9] J. Boonstra, P. Rijken, B. Humbel, F. Cremers, A. Verkleij,
and P. Van Bergen en Henegouwen, “The epidermal growth
factor,” Cell Biology International, vol. 19, no. 5, pp. 413–430,
1995.
[10] N. Prenzel, O. M. Fischer, S. Streit, S. Hart, and A. Ullrich,
“The epidermal growth factor receptor family as a central
element for cellular signal transduction and diversiﬁcation,”
Endocrine-Related Cancer, vol. 8, no. 1, pp. 11–31, 2001.
[11] Y. Yarden, “The EGFR family and its ligands in human can-
cer: signalling mechanisms and therapeutic opportunities,”
European Journal of Cancer, vol. 37, supplement 4, pp. S3–S8,
2001.
[12] J. M. Lafky, J. A. Wilken, A. T. Baron, and N. J. Maihle,
“Clinical implications of the ErbB/epidermal growth factor
(EGF) receptor family and its ligands in ovarian cancer,”
Biochimica et Biophysica Acta, vol. 1785, no. 2, pp. 232–265,
2008.
[13] A. Zaczek, B. Brandt, and K. P. Bielawski, “The diverse
signaling network of EGFR, HER2, HER3 and HER4 tyro-
sine kinase receptors and the consequences for therapeutic
approaches,” Histology and Histopathology, vol. 20, no. 3, pp.
1005–1015, 2005.
[14] E. Tzahar, H. Waterman, X. Chen, et al., “A hierarchical
network of interreceptor interactions determines signal
transduction by Neu diﬀerentiation factor/neuregulin and
epidermal growth factor,” Molecular & Cellular Biology, vol.
16, no. 10, pp. 5276–5287, 1996.
[ 1 5 ]P .M .G u y ,J .V .P l a t k o ,L .C .C a n t l e y ,R .A .C e r i o n e ,a n dK .
L. Carraway III, “Insect cell-expressed p180(erbB3) possesses
an impaired tyrosine kinase activity,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 91, no. 17, pp. 8132–8136, 1994.
[16] G. D. Plowman, G. S. Whitney, M. G. Neubauer, et al.,
“Molecular cloning and expression of an additional epider-
m a lg r o w t hf a c t o rr e c e p t o r - r e l a t e dg e n e , ”Proceedings of the
National Academy of Sciences of the United States of America,
vol. 87, no. 13, pp. 4905–4909, 1990.
[17] S. L. Sierke, K. Cheng, H.-H. Kim, and J. G. Koland,
“Biochemical characterization of the protein tyrosine kinase
homology domain of the ErbB3 (HER3) receptor protein,”
Biochemical Journal, vol. 322, no. 3, pp. 757–763, 1997.
[18] A. Citri, K. B. Skaria, and Y. Yarden, “The deaf and the
dumb: the biology of ErbB-2 and ErbB-3,” Experimental Cell
Research, vol. 284, no. 1, pp. 54–65, 2003.
[ 1 9 ]S .M o r a n d e l l ,T .S t a s y k ,S .S k v o r t s o v ,S .A s c h e r ,a n dL .A .
Huber, “Quantitative proteomics and phosphoproteomics
reveal novel insights into complexity and dynamics of the
EGFR signaling network,” Proteomics, vol. 8, no. 21, pp.
4383–4401, 2008.
[20] T. E. Adams, N. M. McKern, and C. W. Ward, “Signalling by
the type 1 insulin-like growth factor receptor: interplay with
the epidermal growth factor receptor,” Growth Factors, vol.
22, no. 2, pp. 89–95, 2004.
[21] H. E. Jones, J. M. W. Gee, I. R. Hutcheson, J. M. Knowlden,
D. Barrow, and R. I. Nicholson, “Growth factor receptor
interplayandresistanceincancer,” Endocrine-RelatedCancer,
vol. 13, supplement 1, pp. S45–S51, 2006.
[22] L. Qiu, C. Zhou, Y. Sun, et al., “Crosstalk between EGFR
and TrkB enhances ovarian cancer cell migration and
proliferation,” International Journal of Oncology, vol. 29, no.
4, pp. 1003–1011, 2006.
[23] A.Gschwind,E.Zwick,N.Prenzel,M.Leserer,andA.Ullrich,
“Cell communication networks: epidermal growth factor
receptor transactivation as the paradigm for interreceptor
signal transmission,” Oncogene, vol. 20, no. 13, pp. 1594–
1600, 2001.
[24] D. Shida, J. Kitayama, K. Mori, T. Watanabe, and H. Nagawa,
“Transactivation of epidermal growth factor receptor is
involved in leptin-induced activation of Janus-activated
kinase 2 and extracellular signal-regulated kinase 1/2 in
human gastric cancer cells,” Cancer Research, vol. 65, no. 20,
pp. 9159–9163, 2005.
[ 2 5 ]C .D .A n d la n dA .K .R u s t g i ,“ N oo n e - w a ys t r e e t :c r o s s -
talk between E-cadherin and receptor tyrosine kinase (RTK)
signaling: a mechanism to regulate RTK activity,” Cancer
Biology and Therapy, vol. 4, no. 1, pp. 28–31, 2005.
[26] S. Cabodi, L. Moro, E. Bergatto, et al., “Integrin regulation
of epidermal growth factor (EGF) receptor and of EGF-
dependent responses,” Biochemical Society Transactions, vol.
32, no. 3, pp. 438–442, 2004.
[27] J. Riedemann, M. Takiguchi, M. Sohail, and V. M. Macaulay,
“TheEGFreceptorinteractswiththetype1IGFreceptorand
regulates its stability,” Biochemical and Biophysical Research
Communications, vol. 355, no. 3, pp. 707–714, 2007.
[ 2 8 ]E . - M .H u r ,Y . - S .P a r k ,B .D .L e e ,e ta l . ,“ S e n s i t i z a t i o no f
epidermal growth factor-induced signaling by bradykinin
is mediated by c-Src: implications for a role of lipid
microdomains,” The Journal of Biological Chemistry, vol. 279,
no. 7, pp. 5852–5860, 2004.
[29] Q. Zhang, S. M. Thomas, V. W. Y. Lui, et al., “Phospho-
rylation of TNF-α converting enzyme by gastrin-releasing
peptide induces amphiregulin release and EGF receptor
activation,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 103, no. 18, pp. 6901–6906,
2006.
[30] S. Miyamoto, H. Yagi, F. Yotsumoto, T. Kawarabayashi,
and E. Mekada, “Heparin-binding epidermal growth factor-
like growth factor as a novel targeting molecule for cancer
therapy,” Cancer Science, vol. 97, no. 5, pp. 341–347, 2006.
[31] S. Yu, M. M. Murph, Y. Lu, et al., “Lysophosphatidic acid
receptors determine tumorigenicity and aggressiveness of
ovarian cancer cells,” Journal of the National Cancer Institute,
vol. 100, no. 22, pp. 1630–1642, 2008.
[32] G. B. Mills and W. H. Moolenaar, “The emerging role of
lysophosphatidic acid in cancer,” Nature Reviews Cancer, vol.
3, no. 8, pp. 582–591, 2003.
[33] X. Fang, M. Schummer, M. Mao, et al., “Lysophosphatidic
acid is a bioactive mediator in ovarian cancer,” Biochimica et
Biophysica Acta, vol. 1582, no. 1–3, pp. 257–264, 2002.
[34] X. Yu, L. Liu, B. Cai, Y. He, and X. Wan, “Suppression of
anoikis by the neurotrophic receptor TrkB in human ovarian
cancer,” Cancer Science, vol. 29, no. 3, pp. 543–552, 2008.14 Journal of Oncology
[35] J. Vermeij, E. Teugels, C. Bourgain, et al., “Genomic acti-
vation of the EGFR and HER2-neu genes in a signiﬁcant
proportion of invasive epithelial ovarian cancers,” BMC
Cancer, vol. 8, article 3, 2008.
[36] S. Stadlmann, U. Gueth, U. Reiser, et al., “Epithelial growth
factor receptor status in primary and recurrent ovarian
cancer,” Modern Pathology, vol. 19, no. 4, pp. 607–610,
2006.
[37] R. J. Schilder, M. W. Sill, X. Chen, et al., “Phase II study of
geﬁtinib in patients with relapsed or persistent ovarian or
primary peritoneal carcinoma and evaluation of epidermal
growth factor receptor mutations and immunohistochemical
expression: a Gynecologic Oncology Group Study,” Clinical
Cancer Research, vol. 11, no. 15, pp. 5539–5548, 2005.
[38] D.K.Moscatello,M.Holgado-Madruga,A.K.Godwin,etal.,
“Frequent expression of a mutant epidermal growth factor
receptor in multiple human tumors,” Cancer Research, vol.
55, no. 23, pp. 5536–5539, 1995.
[39] K. D. Steﬀensen, M. Waldstrøm, D. Olsen, et al., “Mutant
epidermal growth factor receptor in benign, borderline, and
malignant ovarian tumors,” Clinical Cancer Research, vol. 14,
no. 11, pp. 3278–3282, 2008.
[ 4 0 ]C . - H .L e e ,D .G .H u n t s m a n ,M .C .U .C h e a n g ,e ta l . ,
“Assessment of Her-1, Her-2, and Her-3 expression and
Her-2 ampliﬁcation in advanced stage ovarian carcinoma,”
International Journal of Gynecological Pathology, vol. 24, no.
2, pp. 147–152, 2005.
[41] J. S. Nielsen, E. Jakobsen, B. Hølund, K. Bertelsen, and A.
Jakobsen, “Prognostic signiﬁcance of p53, Her-2, and EGFR
overexpression in borderline and epithelial ovarian cancer,”
International Journal of Gynecological Cancer, vol. 14, no. 6,
pp. 1086–1096, 2004.
[42] A.-R. Hanauske, C. L. Arteaga, G. M. Clark, et al., “Deter-
mination of transforming growth factor activity in eﬀusions
from cancer patients,” Cancer, vol. 61, no. 9, pp. 1832–1837,
1988.
[43] K. Morishige, H. Kurachi, K. Amemiya, et al., “Evidence for
the involvement of transforming growth factor α and epider-
mal growth factor receptor autocrine growth mechanism in
primary human ovarian cancers in vitro,” Cancer Research,
vol. 51, no. 19, pp. 5322–5328, 1991.
[44] H. Kurachi, H. Adachi, K.-I. Morishige, et al., “Transforming
growth factor-α promotes tumor markers secretion from
h u m a no v a r i a nc a n c e r si nv i t r o , ”Cancer,v o l .7 8 ,n o .5 ,p p .
1049–1054, 1996.
[45] M. Ueda, H. Fujii, K. Yoshizawa, et al., “Eﬀects of sex steroids
a n dg r o w t hf a c t o r so ni n v a s i v ea c t i v i t ya n d5  -deoxy-5-
ﬂuorouridine sensitivity in ovarian adenocarcinoma OMC-3
cells,” Japanese Journal of Cancer Research, vol. 89, no. 12, pp.
1334–1342, 1998.
[46] E. Henic, M. Sixt, S. Hansson, G. Høyer-Hansen, and
B. Cassl´ en, “EGF-stimulated migration in ovarian cancer
cells is associated with decreased internalization, increased
surface expression, and increased shedding of the urokinase
plasminogen activator receptor,” Gynecologic Oncology, vol.
101, no. 1, pp. 28–39, 2006.
[ 4 7 ]L . - Z .L i u ,X . - W .H u ,C .X i a ,e ta l . ,“ R e a c t i v eo x y g e ns p e c i e s
regulate epidermal growth factor-induced vascular endothe-
lialgrowthfactorandhypoxia-induciblefactor-1αexpression
through activation of AKT and P70S6K1 in human ovarian
cancer cells,” Free Radical Biology and Medicine, vol. 41, no.
10, pp. 1521–1533, 2006.
[48] M. Campiglio, S. Ali, P. G. Knyazev, and A. Ullrich,
“Characteristics of EGFR family-mediated HRG signals in
human ovarian cancer,” Journal of Cellular Biochemistry, vol.
73, no. 4, pp. 522–532, 1999.
[ 4 9 ]D .Y e ,J .M e n d e l s o h n ,a n dZ .F a n ,“ A u g m e n t a t i o no fa
humanized anti-HER2 mAb 4D5 induced growth inhibition
by a human-mouse chimeric anti-EGF receptor mAb C225,”
Oncogene, vol. 18, no. 3, pp. 731–738, 1999.
[50] F.Vacca,A.Bagnato,K.J.Cart,andR.Tecce,“Transactivation
of the epidermal growth factor receptor in endothelin-1-
induced mitogenic signaling in human ovarian carcinoma
cells,” Cancer Research, vol. 60, no. 18, pp. 5310–5317, 2000.
[51] A. Bagnato, R. Tecce, C. Moretti, V. Di Castro, D. Spergel,
andK.J.Catt,“AutocrineactionsofendotheIin-1asagrowth
factor in human ovarian carcinoma cells,” Clinical Cancer
Research, vol. 1, no. 9, pp. 1059–1066, 1995.
[52] S. Moraitis, S. P. Langdon, and W. R. Miller, “Endothelin
expression and responsiveness in human ovarian carcinoma
cell lines,” European Journal of Cancer Part A,v o l .3 3 ,n o .4 ,
pp. 661–668, 1997.
[53] M. Shichiri, Y. Hirata, T. Nakajima, et al., “Endothelin-1 is
an autocrine/paracrine growth factor for human cancer cell
lines,” The Journal of Clinical Investigation,v o l .8 7 ,n o .5 ,p p .
1867–1871, 1991.
[54] M. Colomiere, A. C. Ward, C. Riley, et al., “Cross talk of sig-
nals between EGFR and IL-6R through JAK2/STAT3 mediate
epithelial-mesenchymal transition in ovarian carcinomas,”
British Journal of Cancer, vol. 100, no. 1, pp. 134–144, 2009.
[55] L. Rosan` o, R. Cianfrocca, S. Masi, et al., “β-arrestin links
endothelin A receptor to β-catenin signaling to induce
ovarian cancer cell invasion and metastasis,” Proceedings of
the National Academy of Sciences of the United States of
America, vol. 106, no. 8, pp. 2806–2811, 2009.
[56] J. J. Kang, Y. P. Soon, H. S. Ji, et al., “Lysophosphatidic acid
receptor 2 and Gi/Src pathway mediate cell motility through
cyclooxygenase2expressioninCAOV-3ovariancancercells,”
Experimental and Molecular Medicine, vol. 40, no. 6, pp. 607–
616, 2008.
[57] T. C. Hamilton, R. C. Young, and K. G. Louie, “Character-
ization of a xenograft model of human ovarian carcinoma
which produces ascites and intraabdominal carcinomatosis
in mice,” Cancer Research, vol. 44, no. 11, pp. 5286–5290,
1984.
[58] K. Garson, T. J. Shaw, K. V. Clark, D.-S. Yao, and B. C.
Vanderhyden, “Models of ovarian cancer—are we there yet?”
Molecular and Cellular Endocrinology, vol. 239, no. 1-2, pp.
15–26, 2005.
[59] W. Shan and J. Liu, “Epithelial ovarian cancer: focus on
geneticsandanimalmodels,”Cell Cycle,vol.8,no.5,pp.731–
735, 2009.
[60] K. D. S. Stakleﬀ and V. E. Von Gruenigen, “Rodent models
for ovarian cancer research,” International Journal of Gyneco-
logical Cancer, vol. 13, no. 4, pp. 405–412, 2003.
[61] B. C. Vanderhyden, T. J. Shaw, and J.-F. Ethier, “Ani-
mal models of ovarian cancer,” Reproductive Biology and
Endocrinology, vol. 1, article 67, 2003.
[62] W. U. Gardner, “Tumorigenesis in transplanted irradiated
and nonirradiated ovaries,” Journal of the National Cancer
Institute, vol. 26, pp. 829–853, 1961.
[63] T. Krarup, “Oocyte destruction and ovarian tumorigenesis
after direct application of a chemical carcinogen (9:0-
dimethyl-1:2-benzanthrene) to the mouse ovary,” Interna-
tional Journal of Cancer, vol. 4, no. 1, pp. 61–75, 1969.Journal of Oncology 15
[64] K.F.Roby,C.C.Taylor,J.P.Sweetwood, etal.,“Development
of a syngeneic mouse model for events related to ovarian
cancer,” Carcinogenesis, vol. 21, no. 4, pp. 585–591, 2000.
[65] E.C.Holland,W.P.Hively,R.A.DePinho,andH.E.Varmus,
“A constitutively active epidermal growth factor receptor
cooperates with disruption of G1 cell-cycle arrest pathways
to induce glioma-like lesions in mice,” Genes & Development,
vol. 12, no. 23, pp. 3675–3685, 1998.
[ 6 6 ]K .P o l i t i ,M .F .Z a k o w s k i ,P . - D .F a n ,E .A .S c h o n f e l d ,W .
Pao, and H. E. Varmus, “Lung adenocarcinomas induced in
mice by mutant EGF receptors found in human lung cancers
respond to a tyrosine kinase inhibitor or to down-regulation
of the receptors,” Genes & Development, vol. 20, no. 11, pp.
1496–1510, 2006.
[ 6 7 ]D .M .D i n u l e s c u ,T .A .I n c e ,B .J .Q u a d e ,S .A .S h a f e r ,
D. Crowley, and T. Jacks, “Role of K-ras and Pten in
the development of mouse models of endometriosis and
endometrioid ovarian cancer,” Nature Medicine, vol. 11, no.
1, pp. 63–70, 2005.
[68] M. J. Palayekar and T. J. Herzog, “The emerging role
of epidermal growth factor receptor inhibitors in ovarian
cancer,” InternationalJournalofGynecologicalCancer,vol.18,
no. 5, pp. 879–890, 2008.
[69] C.L.Arteaga,“Overviewofepidermalgrowthfactorreceptor
biology and its role as a therapeutic target in human
neoplasia,” Seminars in Oncology, vol. 29, no. 5, supplement
14, pp. 3–9, 2002.
[70] C. F. Nicodemus and J. S. Berek, “Monoclonal antibody
therapy of ovarian cancer,” Expert Review of Anticancer
Therapy, vol. 5, no. 1, pp. 87–96, 2005.
[71] T. G. Johns, T. E. Adams, J. R. Cochran, et al., “Identiﬁcation
o ft h ee p i t o p ef o rt h ee p i d e r m a lg r o w t hf a c t o rr e c e p t o r -
speciﬁcmonoclonalantibody806revealsthatitpreferentially
recognizesanuntetheredformofthereceptor,”TheJournalof
BiologicalChemistry,vol.279,no.29,pp.30375–30384,2004.
[72] S. Li, K. R. Schmitz, P. D. Jeﬀrey, J. J. W. Wiltzius, P. Kussie,
and K. M. Ferguson, “Structural basis for inhibition of the
epidermal growth factor receptor by cetuximab,” Cancer Cell,
vol. 7, no. 4, pp. 301–311, 2005.
[ 7 3 ]U .M u r t h y ,A .B a s u ,U .R o d e c k ,M .H e r l y n ,A .H .R o s s ,a n d
M. Das, “Binding of an antagonistic monoclonal antibody
to an intact and fragmented EGF-receptor polypeptide,”
Archives of Biochemistry and Biophysics, vol. 252, no. 2, pp.
549–560, 1987.
[74] Z. Fan, Y. Lu, X. Wu, and J. Mendelsohn, “Antibody-induced
epidermal growth factor receptor dimerization mediates
inhibition of autocrine proliferation of A431 squamous
carcinomacells,”TheJournalofBiologicalChemistry,vol.269,
no. 44, pp. 27595–27602, 1994.
[ 7 5 ]X . - D .Y a n g ,X . - C .J i a ,J .R .F .C o r v a l a n ,P .W a n g ,a n dC .G .
Davis, “Development of ABX-EGF, a fully human anti-EGF
receptor monoclonal antibody, for cancer therapy,” Critical
Reviews in Oncology/Hematology, vol. 38, no. 1, pp. 17–23,
2001.
[76] H. Sunada, B. E. Magun, J. Mendelsohn, and C. L.
MacLeod, “Monoclonal antibody against epidermal growth
factor receptor is internalized without stimulating receptor
phosphorylation,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 83, no. 11, pp.
3825–3829, 1986.
[77] V. Gr¨ unwald and M. Hidalgo, “Developing inhibitors of
the epidermal growth factor receptor for cancer treatment,”
Journal of the National Cancer Institute, vol. 95, no. 12, pp.
851–867, 2003.
[78] R. Mandic, C. J. Rodgarkia-Dara, L. Zhu, et al., “Treatment
of HNSCC cell lines with the EGFR-speciﬁc inhibitor
cetuximab (Erbitux) results in paradox phosphorylation of
tyrosine 1173 in the receptor,” FEBS Letters, vol. 580, no. 20,
pp. 4793–4800, 2006.
[79] Y. Lu, X. Li, K. Liang, et al., “Epidermal growth factor
receptor (EGFR) ubiquitination as a mechanism of acquired
resistance escaping treatment by the anti-EGFR monoclonal
antibody cetuximab,” Cancer Research, vol. 67, no. 17, pp.
8240–8247, 2007.
[80] M. V. Karamouzis, J. R. Grandis, and A. Argiris, “Thera-
pies directed against epidermal growth factor receptor in
aerodigestive carcinomas,” Journal of the American Medical
Association, vol. 298, no. 1, pp. 70–82, 2007.
[ 8 1 ]S . - M .H u a n g ,J .M .B o c k ,a n dP .M .H a r a r i ,“ E p i d e r m a l
growth factor receptor blockade with C225 modulates pro-
liferation, apoptosis, and radiosensitivity in squamous cell
carcinomas of the head and neck,” Cancer Research, vol. 59,
no. 8, pp. 1935–1940, 1999.
[82] Y. Kawaguchi, K. Kono, K. Mimura, H. Sugai, H. Akaike, and
H. Fujii, “Cetuximab induce antibody-dependent cellular
cytotoxicity against EGFR-expressing esophageal squamous
cell carcinoma,” International Journal of Cancer, vol. 120, no.
4, pp. 781–787, 2007.
[83] E. Friedl¨ andera, M. Barok, J. Sz¨ oll˝ osia, and G. Vereb, “ErbB-
directed immunotherapy: antibodies in current practice and
promising new agents,” Immunology Letters, vol. 116, no. 2,
pp. 126–140, 2008.
[84] F. Rivera, M. E. Vega-Villegas, M. F. Lopez-Brea, and R.
Marquez, “Current situation of panitumumab, matuzumab,
nimotuzumab and zalutumumab,” Acta Oncologica, vol. 47,
no. 1, pp. 9–19, 2008.
[85] J. Mendelsohn, “Epidermal growth factor receptor inhibition
by a monoclonal antibody as anticancer therapy,” Clinical
Cancer Research, vol. 3, no. 12, pp. 2703–2707, 1997.
[86] C. J. Bruns, M. T. Harbison, D. W. Davis, et al., “Epidermal
growth factor receptor blockade with C225 plus gemcitabine
results in regression of human pancreatic carcinoma growing
orthotopically in nude mice by antiangiogenic mechanisms,”
Clinical Cancer Research, vol. 6, no. 5, pp. 1936–1948, 2000.
[87] P. Perrotte, T. Matsumoto, K. Inoue, et al., “Anti-epidermal
growth factor receptor antibody C225 inhibits angiogenesis
in human transitional cell carcinoma growing orthotopically
innudemice,”ClinicalCancerResearch,vol.5,no.2,pp.257–
265, 1999.
[88] N. I. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, and J.
Mendelsohn, “Biological eﬃcacy of a chimeric antibody to
the epidermal growth factor receptor in a human tumor
xenograft model,” Clinical Cancer Research, vol. 1, no. 11, pp.
1311–1318, 1995.
[89] M. Prewett, M. Rothman, H. Waksal, M. Feldman, N. H.
Bander, and D. J. Hicklin, “Mouse-human chimeric anti-
epidermal growth factor receptor antibody C225 inhibits the
growth of human renal cell carcinoma xenografts in nude
mice,” ClinicalCancerResearch,vol. 4, no. 12, pp. 2957–2966,
1998.
[90] J. P. Overholser, M. C. Prewett, A. T. Hooper, H. W.
Waksal, and D. J. Hicklin, “Epidermal growth factor receptor
blockade by antibody IMC-C225 inhibits growth of a human
pancreatic carcinoma xenograft in nude mice,” Cancer, vol.
89, no. 1, pp. 74–82, 2000.
[91] D. Raben, B. Helfrich, D. C. Chan, et al., “The eﬀects of
cetuximab alone and in combination with radiation and/or16 Journal of Oncology
chemotherapy in lung cancer,” Clinical Cancer Research, vol.
11, no. 2, pp. 795–805, 2005.
[92] S. Kim, C. N. Prichard, M. N. Younes, et al., “Cetuximab
andirinotecaninteractsynergisticallytoinhibitthegrowthof
orthotopic anaplastic thyroid carcinoma xenografts in nude
mice,” Clinical Cancer Research, vol. 12, no. 2, pp. 600–607,
2006.
[93] J. L. Eller, S. L. Longo, D. J. Hicklin, et al., “Activity of anti-
epidermalgrowthfactorreceptormonoclonalantibodyC225
against glioblastoma multiforme,” Neurosurgery, vol. 51, no.
4, pp. 1005–1014, 2002.
[94] A. D. Jensen, M. W. M¨ unter, H. Bischoﬀ, et al., “Treatment
of non-small cell lung cancer with intensity-modulated
radiation therapy in combination with cetuximab: the NEAR
protocol (NCT00115518),” BMC Cancer, vol. 6, article 122,
2006.
[95] C. Delbaldo, J.-Y. Pierga, V. Dieras, et al., “Pharmacokinetic
proﬁle of cetuximab (Erbitux
TM alone and in combination
with irinotecan in patients with advanced EGFR-positive
adenocarcinoma,”EuropeanJournalofCancer,vol.41,no.12,
pp. 1739–1745, 2005.
[96] R. J. Schilder, H. B. Pathak, A. E. Lokshin, et al., “Phase II
trial of single agent cetuximab in patients with persistent or
recurrent epithelial ovarian or primary peritoneal carcinoma
with the potential for dose escalation to rash,” Gynecologic
Oncology, vol. 113, no. 1, pp. 21–27, 2009.
[ 9 7 ]A .A .S e c o r d ,J .A .B l e s s i n g ,D .K .A r m s t r o n g ,e ta l . ,“ P h a s e
II trial of cetuximab and carboplatin in relapsed platinum-
sensitive ovarian cancer and evaluation of epidermal growth
factor receptor expression: a Gynecologic Oncology Group
study,” Gynecologic Oncology, vol. 108, pp. 493–499, 2008.
[98] J. Konner, R. J. Schilder, F. A. DeRosa, et al., “A phase II study
of cetuximab/paclitaxel/carboplatin for the initial treatment
of advanced-stage ovarian, primary peritoneal, or fallopian
tube cancer,” Gynecologic Oncology, vol. 110, no. 2, pp. 140–
145, 2008.
[99] M. V. Seiden, H. A. Burris, U. Matulonis, et al., “A phase II
trial of EMD72000 (matuzumab), a humanized anti-EGFR
monoclonal antibody, in patients with platinum-resistant
ovarian and primary peritoneal malignancies,” Gynecologic
Oncology, vol. 104, no. 3, pp. 727–731, 2007.
[100] K. T. Flaherty and M. S. Brose, “Her-2 targeted therapy:
beyond breast cancer and trastuzumab,” Current Oncology
Reports, vol. 8, no. 2, pp. 90–95, 2006.
[101] M. A. Bookman, K. M. Darcy, D. Clarke-Pearson, R. A.
Boothby, and I. R. Horowitz, “Evaluation of monoclonal
humanized anti-HER2 antibody, trastuzumab, in patients
with recurrent or refractory ovarian or primary peritoneal
carcinoma with overexpression of HER2: a phase II trial
of the Gynecologic Oncology Group,” Journal of Clinical
Oncology, vol. 21, no. 2, pp. 283–290, 2003.
[102] S. R. Young, W.-H. Liu, J.-A. Brock, and S. T. Smith, “ERBB2
and chromosome 17 centromere studies of ovarian cancer by
ﬂuorescence in situ hybridization,” Genes Chromosomes and
Cancer, vol. 16, no. 2, pp. 130–137, 1996.
[103] D. Glenn, F. Ueland, A. Bicher, et al., “A randomized phase II
trialwithgemcitabinewithorwithoutpertuzumab(rhuMAb
2C4) in platinum-resistant ovarian cancer (OC): preliminary
safety data,” Journal of Clinical Oncology, vol. 24, p. 13001,
2006.
[104] Y. Wang, J. Hailey, D. Williams, et al., “Inhibition of insulin-
like growth factor-I receptor (IGF-IR) signaling and tumor
cell growth by a fully human neutralizing anti-IGF-IR
antibody,” Molecular Cancer Therapeutics,v o l .4 ,n o .8 ,p p .
1214–1221, 2005.
[105] E. K. Maloney, J. L. McLaughlin, N. E. Dagdigian, et al., “An
anti-insulin-like growth factor I receptor antibody that is a
potentinhibitorofcancercellproliferation,”CancerResearch,
vol. 63, no. 16, pp. 5073–5083, 2003.
[106] J. Singh, E. M. Dobrusin, D. W. Fry, T. Haske, A. Whitty,
and D. J. McNamara, “Structure-based design of a potent,
selective, and irreversible inhibitor of the catalytic domain
of the erbB receptor subfamily of protein tyrosine kinases,”
Journal of Medicinal Chemistry, vol. 40, no. 7, pp. 1130–1135,
1997.
[107] J. D. Moyer, E. G. Barbacci, K. K. Iwata, et al., “Induction
of apoptosis and cell cycle arrest by CP-358,774, an inhibitor
of epidermal growth factor receptor tyrosine kinase,” Cancer
Research, vol. 57, no. 21, pp. 4838–4848, 1997.
[108] E. K. Rowinsky, “The erbB family: targets for therapeu-
tic development against cancer and therapeutic strategies
using monoclonal antibodies and tyrosine kinase inhibitors,”
Annual Review of Medicine, vol. 55, pp. 433–457, 2004.
[109] C. L. Arteaga, T. T. Ramsey, L. K. Shawver, and C. A. Guyer,
“Unliganded epidermal growth factor receptor dimerization
induced by direct interaction of quinazolines with the ATP
binding site,” The Journal of Biological Chemistry, vol. 272,
no. 37, pp. 23247–23254, 1997.
[110] J. Albanell and P. Gasc´ on, “Small molecules with EGFR-TK
inhibitor activity,” Current Drug Targets,v o l .6 ,n o .3 ,p p .
259–274, 2005.
[111] J. M. Sewell, K. G. Macleod, A. Ritchie, J. F. Smyth, and S.
P. Langdon, “Targeting the EGF receptor in ovarian cancer
with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’),” British
Journal of Cancer, vol. 86, no. 3, pp. 456–462, 2002.
[112] R. J. Schilder, M. W. Sill, X. Chen, et al., “Phase II study of
geﬁtinib in patients with relapsed or persistent ovarian or
primary peritoneal carcinoma and evaluation of epidermal
growth factor receptor mutations and immunohistochemical
expression: a Gynecologic Oncology Group Study,” Clinical
Cancer Research, vol. 11, no. 15, pp. 5539–5548, 2005.
[113] E. M. Posadas, M. S. Liel, V. Kwitkowski, et al., “A phase
II and pharmacodynamic study of geﬁtinib in patients with
refractoryorrecurrentepithelialovariancancer,”Cancer,vol.
109, no. 7, pp. 1323–1330, 2007.
[114] D. B. Costa, S. Kobayashi, D. G. Tenen, and M. S. Huber-
man, “Pooled analysis of the prospective trials of geﬁtinib
monotherapyforEGFR-mutantnon-smallcelllungcancers,”
Lung Cancer, vol. 58, no. 1, pp. 95–103, 2007.
[115] U. Wagner, A. du Bois, J. Pﬁsterer, et al., “Geﬁtinib in
combination with tamoxifen in patients with ovarian cancer
refractory or resistant to platinum-taxane based therapy—
a phase II trial of the AGO Ovarian Cancer Study Group
(AGO-OVAR 2.6),” Gynecologic Oncology, vol. 105, no. 1, pp.
132–137, 2007.
[116] A. N. Gordon, N. Finkler, R. P. Edwards, et al., “Eﬃcacy
and safety of erlotinib HCl, an epidermal growth factor
receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients
with advanced ovarian carcinoma: results from a phase
II multicenter study,” International Journal of Gynecological
Cancer, vol. 15, no. 5, pp. 785–792, 2005.
[117] H. S. Nimeiri, A. M. Oza, R. J. Morgan, et al., “Eﬃcacy
and safety of bevacizumab plus erlotinib for patients with
recurrent ovarian, primary peritoneal, and fallopian tube
cancer: a trial of the Chicago, PMH, and California Phase II
Consortia,” Gynecologic Oncology, vol. 110, no. 1, pp. 49–55,
2008.Journal of Oncology 17
[118] P. A. Vasey, M. Gore, R. Wilson, et al., “A phase Ib trial of
docetaxel,carboplatinanderlotinibinovarian,fallopiantube
and primary peritoneal cancers,” British Journal of Cancer,
vol. 98, no. 11, pp. 1774–1780, 2008.
[119] M. W. Saif, A. Elﬁky, and R. R. Salem, “Gastrointestinal
perforation due to bevacizumab in colorectal cancer,” Annals
of Surgical Oncology, vol. 14, no. 6, pp. 1860–1869, 2007.
[120] P. A. Vasey, G. C. Jayson, A. Gordon, et al., “Phase III
randomized trial of docetaxel-carboplatin versus paclitaxel-
carboplatinasﬁrst-linechemotherpyforovariancarcinoma,”
Journal of the National Cancer Institute, vol. 96, no. 22, pp.
1682–1691, 2004.
[121] W. Xia, R. J. Mullin, B. R. Keith, et al., “Anti-tumor activity
of GW572016: a dual tyrosine kinase inhibitor blocks EGF
activation of EGFR/erbB2 and downstream Erk1/2 and AKT
pathways,” Oncogene, vol. 21, no. 41, pp. 6255–6263, 2002.
[122] K. J. Kimball, T. M. Numnum, T. O. Kirby, et al., “A phase I
studyoflapatinibincombinationwithcarboplatininwomen
with platinum sensitive recurrent ovarian carcinoma,” Gyne-
cologic Oncology, vol. 111, no. 1, pp. 95–101, 2008.
[123] S. Campos, O. Hamid, M. V. Seiden, et al., “Multicenter, ran-
domized phase II trial of oral CI-1033 for previously treated
advanced ovarian cancer,” Journal of Clinical Oncology, vol.
23, no. 24, pp. 5597–5604, 2005.
[124] D. Li, L. Ambrogio, T. Shimamura, et al., “BIBW2992,
an irreversible EGFR/HER2 inhibitor highly eﬀective in
preclinicallungcancermodels,”Oncogene,vol.27,no.34,pp.
4702–4711, 2008.
[125] P. Traxler, P. R. Allegrini, R. Brandt, et al., “AEE788: a dual
family epidermal growth factor receptor/ErbB2 and vascular
endothelial growth factor receptor tyrosine kinase inhibitor
withantitumorandantiangiogenicactivity,”CancerResearch,
vol. 64, no. 14, pp. 4931–4941, 2004.
[126] S.-F. Huang, H.-P. Liu, L.-H. Li, et al., “High frequency of
epidermal growth factor receptor mutations with complex
patterns in non-small cell lung cancers related to geﬁtinib
responsiveness in Taiwan,” Clinical Cancer Research, vol. 10,
no. 24, pp. 8195–8203, 2004.
[127] T. J. Lynch, D. W. Bell, R. Sordella, et al., “Activating muta-
tions in the epidermal growth factor receptor underlying
responsiveness of non-small-cell lung cancer to geﬁtinib,”
The New England Journal of Medicine, vol. 350, no. 21, pp.
2129–2139, 2004.
[128] J. G. Paez, P. A. J¨ anne, J. C. Lee, et al., “EGFR mutations in
lung, cancer: correlation with clinical response to geﬁtinib
therapy,” Science, vol. 304, no. 5676, pp. 1497–1500, 2004.
[129] W. Pao, V. Miller, M. Zakowski, et al., “EGF receptor
gene mutations are common in lung cancers from “never
smokers” and are associated with sensitivity of tumors to
geﬁtinib and erlotinib,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 101, no. 36, pp.
13306–13311, 2004.
[130] L.Lacroix,P.Pautier,P.Duvillard,etal.,“Responseofovarian
carcinomas to geﬁtinib-carboplatin-paclitaxel combination
is not associated with EGFR kinase domain somatic muta-
tions,” International Journal of Cancer, vol. 118, no. 4, pp.
1068–1069, 2006.
[131] S. Ramalingam, J. Forster, C. Naret, et al., “Dual inhibition
of the epidermal growth factor receptor with cetuximab,
an IgG1 monoclonal antibody, and geﬁtinib, a tyrosine
kinase inhibitor, in patients with refractory non-small cell
lung cancer (NSCLC): a phase I study,” Journal of Thoracic
Oncology, vol. 3, no. 3, pp. 258–264, 2008.
[132] L. Toschi and F. Cappuzzo, “Understanding the new genetics
of responsiveness to epidermal growth factor receptor tyro-
sinekinaseinhibitors,”TheOncologist,vol.12,no.2,pp.211–
220, 2007.
[133] F. Morgillo and H.-Y. Lee, “Resistance to epidermal growth
factor receptor-targeted therapy,” Drug Resistance Updates,
vol. 8, no. 5, pp. 298–310, 2005.
[134] P. Duesberg, R. Li, R. Sachs, A. Fabarius, M. B. Upender, and
R. Hehlmann, “Cancer drug resistance: the central role of the
karyotype,” Drug Resistance Updates, vol. 10, no. 1-2, pp. 51–
58, 2007.
[135] J. A. Engelman and J. Settleman, “Acquired resistance to
tyrosine kinase inhibitors during cancer therapy,” Current
Opinion in Genetics and Development, vol. 18, no. 1, pp. 73–
79, 2008.
[136] G. Tortora, R. Bianco, G. Daniele, et al., “Overcoming resis-
tance to molecularly targeted anticancer therapies: rational
drug combinations based on EGFR and MAPK inhibition
for solid tumours and haematologic malignancies,” Drug
Resistance Updates, vol. 10, no. 3, pp. 81–100, 2007.
[137] I. Martinez-Lacaci, P. Garcia Morales, J. L. Soto, and M.
Saceda, “Tumour cells resistance in cancer therapy,” Clinical
and Translational Oncology, vol. 9, no. 1, pp. 13–20, 2007.
[138] R. Bianco, V. Damiano, T. Gelardi, G. Daniele, F. Ciardiello,
and G. Tortora, “Rational combination of targeted therapies
as a strategy to overcome the mechanisms of resistance
to inhibitors of EGFR signaling,” Current Pharmaceutical
Design, vol. 13, no. 33, pp. 3358–3367, 2007.
[139] F. Morgillo, M. A. Bareschino, R. Bianco, G. Tortora, and F.
Ciardiello, “Primary and acquired resistance to anti-EGFR
targeted drugs in cancer therapy,” Diﬀerentiation, vol. 75, no.
9, pp. 788–799, 2007.
[140] Z. Weihua, R. Tsan, W.-C. Huang, et al., “Survival of cancer
cells is maintained by EGFR independent of its kinase
activity,” Cancer Cell, vol. 13, no. 5, pp. 385–393, 2008.
[141] R. A. Gatenby and R. J. Gillies, “Why do cancers have high
aerobic glycolysis?” Nature Reviews Cancer, vol. 4, no. 11, pp.
891–899, 2004.
[142] K. Krysan, J. M. Lee, M. Dohadwala, et al., “Inﬂammation,
epithelial to mesenchymal transition, and epidermal growth
factor receptor tyrosine kinase inhibitor resistance,” Journal
of Thoracic Oncology, vol. 3, no. 2, pp. 107–110, 2008.
[143] M. P. Morelli, T. Cascone, T. Troiani, et al., “Sequence-
dependent antiproliferative eﬀects of cytotoxic drugs and
epidermal growth factor receptor inhibitors,” Annals of
Oncology, vol. 16, supplement 4, pp. iv61–iv68, 2005.
[144] B. J. B. Simpson, J. Weatherill, E. P. Miller, A. M. Lessells, S.
P. Langdon, and W. R. Miller, “c-erbB-3 protein expression
in ovarian tumours,” British Journal of Cancer, vol. 71, no. 4,
pp. 758–762, 1995.
[145] B. Tanner, D. Hasenclever, K. Stern, et al., “ErbB-3 predicts
survival in ovarian cancer,” Journal of Clinical Oncology, vol.
24, no. 26, pp. 4317–4323, 2006.
[146] A. C. Hsieh and M. M. Moasser, “Targeting HER proteins in
cancer therapy and the role of the non-target HER3,” British
Journal of Cancer, vol. 97, no. 4, pp. 453–457, 2007.
[147] J.G.Christensen,R.E.Schreck,E.Chan,etal.,“Highlevelsof
HER-2 expression alter the ability of epidermal growth factor
receptor (EGFR) family tyrosine kinase inhibitors to inhibit
EGFRphosphorylationinvivo,”ClinicalCancerResearch,vol.
7, no. 12, pp. 4230–4238, 2001.18 Journal of Oncology
[148] N. V. Sergina, M. Rausch, D. Wang, et al., “Escape from
HER-family tyrosine kinase inhibitor therapy by the kinase-
inactive HER3,” Nature, vol. 445, no. 7126, pp. 437–441,
2007.
[149] Q.-B. She, D. Solit, A. Basso, and M. M. Moasser, “Resistance
to geﬁtinib in PTEN-Null HER-overexpressing tumor cells
can be overcome through restoration of PTEN function
or pharmacologic modulation of constitutive phosphatidyli-
nositol 3 -kinase/Akt pathway signaling,” Clinical Cancer
Research, vol. 9, no. 12, pp. 4340–4346, 2003.
[150] R. Bianco, I. Shin, C. A. Ritter, et al., “Loss of
PTEN/MMAC1/TEP in EGF receptor-expressing tumor
cells counteracts the antitumor action of EGFR tyrosine
kinase inhibitors,” Oncogene, vol. 22, no. 18, pp. 2812–2822,
2003.
[151] E.Massarelli,M.Varella-Garcia,X.Tang,etal.,“KRASmuta-
tion is an important predictor of resistance to therapy with
epidermal growth factor receptor tyrosine kinase inhibitors
in non-small cell lung cancer,” Clinical Cancer Research, vol.
13, no. 10, pp. 2890–2896, 2007.
[152] A. Lievre, J.-B. Bachet, D. Le Corre, et al., “KRAS mutation
status is predictive of response to cetuximab therapy in
colorectal cancer,” Cancer Research, vol. 66, no. 8, pp. 3992–
3995, 2006.
[153] V. A. Miller, G. J. Riely, M. F. Zakowski, et al., “Molecular
characteristics of bronchioloalveolar carcinoma and adeno-
carcinoma, bronchioloalveolar carcinoma subtype, predict
response to erlotinib,” Journal of Clinical Oncology, vol. 26,
no. 9, pp. 1472–1478, 2008.
[154] V. Auner, G. Kriegsh¨ auser, D. Tong, et al., “KRAS mutation
analysis in ovarian samples using a high sensitivity biochip
assay,” BMC Cancer, vol. 9, article 111, 2009.
[155] M. Liu, M. S. Bryant, J. Chen, et al., “Antitumor activity
of SCH 66336, an orally bioavailable tricyclic inhibitor
of farnesyl protein transferase, in human tumor xenograft
models and wap-ras transgenic mice,” Cancer Research, vol.
58, no. 21, pp. 4947–4956, 1998.
[156] C. Desbois-Mouthon, W. Cacheux, M.-J. Blivet-Van
Eggelpoel, et al., “Impact of IGF-1R/EGFR cross-talks on
hepatoma cell sensitivity to geﬁtinib,” International Journal
of Cancer, vol. 119, no. 11, pp. 2557–2566, 2006.
[157] R. Nahta, L. X. H. Yuan, Y. Du, and F. J. Esteva, “Lapatinib
induces apoptosis in trastuzumab-resistant breast cancer
cells: eﬀects on insulin-like growth factor I signaling,”
Molecular Cancer Therapeutics, vol. 6, no. 2, pp. 667–674,
2007.
[158] S. M. Thomas, N. E. Bhola, Q. Zhang, et al., “Cross-talk
between G protein-coupled receptor and epidermal growth
factor receptor signaling pathways contributes to growth and
invasion of head and neck squamous cell carcinoma,” Cancer
Research, vol. 66, no. 24, pp. 11831–11839, 2006.
[159] Q. Zhang, N. E. Bhola, V. W. Y. Lui, et al., “Antitumor
mechanisms of combined gastrin-releasing peptide receptor
and epidermal growth factor receptor targeting in head and
neck cancer,” Molecular Cancer Therapeutics,v o l .6 ,n o .4 ,p p .
1414–1424, 2007.
[160] J. A. Engelman, K. Zejnullahu, T. Mitsudomi, et al., “MET
ampliﬁcation leads to geﬁtinib resistance in lung cancer by
activating ERBB3 signaling,” Science, vol. 316, no. 5827, pp.
1039–1043, 2007.
[161] S. N. Holden, S. G. Eckhardt, R. Basser, et al., “Clinical
evaluation of ZD6474, an orally active inhibitor of VEGF
and EGF receptor signaling, in patients with solid, malignant
tumors,” Annals of Oncology, vol. 16, no. 8, pp. 1391–1397,
2005.
[162] S. Skvortsov, B. Sarg, J. Loeﬄer-Ragg, et al., “Diﬀerent
proteome pattern of epidermal growth factor receptor-
positive colorectal cancer cell lines that are responsive
and nonresponsive to C225 antibody treatment,” Molecular
Cancer Therapeutics, vol. 3, no. 12, pp. 1551–1558, 2004.
[163] S. Nelander, W. Wang, B. Nilsson, et al., “Models from
experiments: combinatorial drug perturbations of cancer
cells,” Molecular Systems Biology, vol. 4, article 216, 2008.
[164] W. Kassouf, C. P. N. Dinney, G. Brown, et al., “Uncoupling
between epidermal growth factor receptor and downstream
signals deﬁnes resistance to the antiproliferative eﬀect of
geﬁtinib in bladder cancer cells,” Cancer Research, vol. 65, no.
22, pp. 10524–10535, 2005.
[165] K. Wang, L. Gan, E. Jeﬀery, et al., “Monitoring gene expres-
sion proﬁle changes in ovarian carcinomas using cDNA
microarray,” Gene, vol. 229, no. 1-2, pp. 101–108, 1999.
[166] M. E. Schaner, D. T. Ross, G. Ciaravino, et al., “Gene expres-
sionpatternsinovariancarcinomas,” MolecularBiologyofthe
Cell, vol. 14, no. 11, pp. 4376–4386, 2003.
[167] Z. E. Selvanayagam, T. H. Cheung, N. Wei, et al., “Prediction
of chemotherapeutic response in ovarian cancer with DNA
microarray expression proﬁling,” Cancer Genetics and Cyto-
genetics, vol. 154, no. 1, pp. 63–66, 2004.
[168] C. M. Coticchia, J. Yang, and M. A. Moses, “Ovarian cancer
biomarkers: current options and future promise,” Journal of
the National Comprehensive Cancer Network,v o l .6 ,n o .8 ,p p .
795–802, 2008.
[169] R. I. Olivier, M. van Beurden, and L. J. van’ t Veer, “The role
of gene expression proﬁling in the clinical management of
ovarian cancer,” European Journal of Cancer, vol. 42, no. 17,
pp. 2930–2938, 2006.
[170] U. McDermott, S. V. Sharma, and J. Settleman, “High-
throughput lung cancer cell line screening for genotype-
correlated sensitivity to an EGFR kinase inhibitor,” Methods
in Enzymology, vol. 438, pp. 331–341, 2008.
[171] D. Calzolari, S. Bruschi, L. Coquin, et al., “Search algorithms
as a framework for the optimization of drug combinations,”
PLoS Computational Biology, vol. 4, no. 12, Article ID
e1000249, 2008.
[172] J. Tapper, E. Kettunen, W. El-Rifai, M. Sepp¨ al¨ a, L. C.
Andersson, and S. Knuutila, “Changes in gene expression
during progression of ovarian carcinoma,” Cancer Genetics
and Cytogenetics, vol. 128, no. 1, pp. 1–6, 2001.
[173] P. Schraml, G. Schwerdtfeger, F. Burkhalter, et al., “Com-
bined array comparative genomic hybridization and tissue
microarray analysis suggest PAK1 at 11q13.5-q14 as a critical
oncogene target in ovarian carcinoma,” American Journal of
Pathology, vol. 163, no. 3, pp. 985–992, 2003.
[174] K. D. Steﬀensen, M. Waldstrøm, R. F. Andersen, et al.,
“Protein levels and gene expressions of the epidermal growth
factor receptors, HER1,H ER2, HER3 and HER4 in benign
and malignant ovarian tumors,” International Journal of
Oncology, vol. 33, no. 1, pp. 195–204, 2008.
[175] ¨ O.Alper,E.S.Bergmann-Leitner,T.A.Bennett,N.F.Hacker,
K. Stromberg, and W. G. Stetler-Stevenson, “Epidermal
growth factor receptor signalling and the invasive phenotype
of ovarian carcinoma cells,” Journal of the National Cancer
Institute, vol. 93, no. 18, pp. 1375–1384, 2001.
[176] Z. Guo, S. Cai, R. Fang, et al., “The synergistic eﬀects of
CXCR4 and EGFR on promoting EGF-mediated metastasisJournal of Oncology 19
in ovarian cancer cells,” Colloids and Surfaces B, vol. 60, no. 1,
pp. 1–6, 2007.
[177] K. R. Kalli, S. V. Bradley, S. Fuchshuber, and C. A. Conover,
“Estrogen receptor-positive human epithelial ovarian carci-
noma cells respond to the antitumor drug suramin with
increased proliferation: possible insight into ER and epider-
mal growth factor signaling interactions in ovarian cancer,”
Gynecologic Oncology, vol. 94, no. 3, pp. 705–712, 2004.
[178] J. Morrison, S. S. Briggs, N. Green, et al., “Virotherapy of
ovarian cancer with polymer-cloaked adenovirus retargeted
to the epidermal growth factor receptor,” Molecular Therapy,
vol. 16, no. 2, pp. 244–251, 2008.
[179] P.A.vanDam,I.B.Vergote,D.G.Lowe,etal.,“Expressionof
c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth
factor receptor I, and epidermal growth factor receptor in
ovarian carcinoma,” Journal of Clinical Pathology, vol. 47, no.
10, pp. 914–919, 1994.
[180] K. D. Cowden Dahl, J. Symowicz, Y. Ning, et al., “Matrix
metalloproteinase9isamediatorofepidermalgrowthfactor-
dependent E-cadherin loss in ovarian carcinoma cells,”
Cancer Research, vol. 68, no. 12, pp. 4606–4613, 2008.
[181] C. Cao, S. Lu, A. Sowa, et al., “Priming with EGFR tyrosine
kinase inhibitor and EGF sensitizes ovarian cancer cells to
respond to chemotherapeutical drugs,” Cancer Letters, vol.
266, no. 2, pp. 249–262, 2008.
[182] N. G. Cloven, A. Kyshtoobayeva, R. A. Burger, I.-R. Yu,
and J. P. Fruehauf, “In vitro chemoresistance and biomarker
proﬁles are unique for histologic subtypes of epithelial
ovariancancer,”GynecologicOncology,vol.92,no.1,pp.160–
166, 2004.
[183] C. Schindlbeck, P. Hantschmann, M. Zerzer, et al., “Prog-
nostic impact of KI67, p53, human epithelial growth factor
receptor 2, topoisomerase IIα,e p i d e r m a lg r o w t hf a c t o r
receptor, and nm23 expression of ovarian carcinomas and
disseminated tumor cells in the bone marrow,” International
JournalofGynecologicalCancer,vol.17,no.5,pp.1047–1055,
2007.
[184] I. Skirnisdottir, T. Seidal, and B. Sorbe, “A new prognostic
modelcomprisingp53,EGFR,andtumorgradeinearlystage
epithelial ovarian carcinoma and avoiding the problem of
inaccurate surgical staging,” International Journal of Gyneco-
logical Cancer, vol. 14, no. 2, pp. 259–270, 2004.
[185] Z. Suo, K. Karbove, C. G. Trope, K. Metodiev, and J. M.
Nesland, “Papillary serous carcinoma of the ovary: an ultra-
structural and immunohistochemical study,” Ultrastructural
Pathology, vol. 28, no. 3, pp. 141–147, 2004.
[186] ¨ O. Alper, M. L. De Santis, K. Stromberg, N. F. Hacker, Y. S.
Cho-Chung, and D. S. Salomon, “Anti-sense suppression of
epidermal growth factor receptor expression alters cellular
proliferation, cell-adhesion and tumorigenicity in ovarian
cancer cells,” International Journal of Cancer, vol. 88, no. 4,
pp. 566–574, 2000.
[187] P. de Graeﬀ,A .P .G .C r i j n s ,K .A .T e nH o o r ,e ta l . ,“ T h eE r b B
signalling pathway: protein expression and prognostic value
inepithelialovariancancer,”BritishJournalofCancer,vol.99,
no. 2, pp. 341–349, 2008.
[188] C. Facco, S. La Rosa, A. Dionigi, S. Uccella, C. Riva, and
C. Capella, “High expression of growth factors and growth
factor receptors in ovarian metastases from ileal carcinoids:
an immunohistochemical study of 2 cases,” Archives of
Pathology and Laboratory Medicine, vol. 122, no. 9, pp. 828–
832, 1998.
[189] G. Ferrandina, F. O. Ranelletti, L. Lauriola, et al.,
“Cyclooxygenase-2 (COX-2), epidermal growth factor recep-
tor (EGFR), and Her-2/neu expression in ovarian cancer,”
Gynecologic Oncology, vol. 85, no. 2, pp. 305–310, 2002.
[190] B. A. Goﬀ, J. A. Ries, L. P. Els, M. D. Coltrera, and A. M.
Gown, “Immunophenotype of ovarian cancer as predictor of
clinical outcome: evaluation at primary surgery and second-
look procedure,” Gynecologic Oncology, vol. 70, no. 3, pp.
378–385, 1998.
[191] A. Harlozinska, J. K. Bar, E. Sobanska, and M. Goluda,
“Epidermal growth factor receptor and c-erbB-2 oncopro-
teins in tissue and tumor eﬀusion cells of histopathologically
diﬀerent ovarian neoplasms,” Tumor Biology, vol. 19, no. 5,
pp. 364–373, 1998.
[192] Y. Kuwashima, T. Uehara, K. Kishi, K. Shiromizu, M.
Matsuzawa, and S. Takayama, “Immunohistochemical char-
acterization of undiﬀerentiated carcinomas of the ovary,”
Journal of Cancer Research and Clinical Oncology, vol. 120,
no. 11, pp. 672–677, 1994.
[193] M. Mandai, I. Konishi, M. Koshiyama, et al., “Expression of
metastasis-related nm23-H1 and nm23-H2 genes in ovarian
carcinomas: correlation with clinicopathology, EGFR, c-
erbB-2, and c-erbB-3 genes, and sex steroid receptor expres-
sion,” Cancer Research, vol. 54, no. 7, pp. 1825–1830, 1994.
[194] I. Skirnisdottir, B. Sorbe, and T. Seidal, “The growth factor
receptors HER-2/neu and EGFR, their relationship, and their
eﬀects on the prognosis in early stage (FIGO I-II) epithelial
ovarian carcinoma,” International Journal of Gynecological
Cancer, vol. 11, no. 2, pp. 119–129, 2001.
[195] C. van Haaften-Day, P. Russell, C. M. Boyer, et al., “Expres-
sionofcellregulatoryproteinsinovarianborderlinetumors,”
Cancer, vol. 77, no. 10, pp. 2092–2098, 1996.
[196] M. Aponte, W. Jiang, M. Lakkis, et al., “Activation of platelet-
activating factor receptor and pleiotropic eﬀects on tyrosine
phospho-EGFR/Src/FAK/paxillin in ovarian cancer,” Cancer
Research, vol. 68, no. 14, pp. 5839–5848, 2008.
[197] B. Nolen, A. Marrangoni, L. Velikokhatnaya, et al., “A
serum based analysis of ovarian epithelial tumorigenesis,”
Gynecologic Oncology, vol. 112, no. 1, pp. 47–54, 2009.
[198] J. K. Chan, H. Pham, X. J. You, et al., “Suppression of ovarian
cancer cell tumorigenicity and evasion of cisplatin resistance
using a truncated epidermal growth factor receptor in a rat
model,” Cancer Research, vol. 65, no. 8, pp. 3243–3248, 2005.
[199] G. Ferrandina, G. Scambia, P. Benedetti Panici, et al., “Eﬀects
of dexamethasone on the growth and epidermal growth
factor receptor expression of the OVCA 433 ovarian cancer
cells,” Molecular and Cellular Endocrinology, vol. 83, no. 2-3,
pp. 183–193, 1992.
[200] S. L. Bull Phelps, J. O. Schorge, M. J. Peyton, et al.,
“Implications of EGFR inhibition in ovarian cancer cell
proliferation,” Gynecologic Oncology, vol. 109, no. 3, pp. 411–
417, 2008.
[201] T. Servidei, A. Riccardi, S. Mozzetti, C. Ferlini, and R.
Riccardi, “Chemoresistant tumor cell lines display altered
epidermal growth factor receptor and HER3 signaling and
enhanced sensitivity to geﬁtinib,” International Journal of
Cancer, vol. 123, no. 12, pp. 2939–2949, 2008.
[202] B. Davidson, V. Espina, S. M. Steinberg, et al., “Proteomic
analysis of malignant ovarian cancer eﬀusions as a tool for
biologic and prognostic proﬁling,” Clinical Cancer Research,
vol. 12, no. 3, pp. 791–799, 2006.
[203] E.M.Posadas,V.Kwitkowski,H.L.Kotz,etal.,“Aprospective
analysis of imatinib-induced c-KIT modulation in ovarian20 Journal of Oncology
cancer: a phase II clinical study with proteomic proﬁling,”
Cancer, vol. 110, no. 2, pp. 309–317, 2007.
[204] J.-H. Choi, K.-C. Choi, N. Auersperg, and P. C. K. Leung,
“Gonadotropins upregulate the epidermal growth factor
receptor through activation of mitogen-activated protein
kinases and phosphatidyl-inositol-3-kinase in human ovar-
iansurfaceepithelialcells,”Endocrine-RelatedCancer,vol.12,
no. 2, pp. 407–421, 2005.
[205] C.Ji,C.Cao,S.Lu,etal.,“CurcuminattenuatesEGF-induced
AQP3 up-regulation and cell migration in human ovarian
cancer cells,” Cancer Chemotherapy and Pharmacology, vol.
62, no. 5, pp. 857–865, 2008.
[206] A. J. Li, D. R. Scoles, K. U. M. Armstrong, and B. Y. Karlan,
“Androgen receptor cytosine-adenine-guanine repeat poly-
morphisms modulate EGFR signaling in epithelial ovarian
carcinomas,” Gynecologic Oncology, vol. 109, no. 2, pp. 220–
225, 2008.
[207] C. Porcile, A. Bajetto, F. Barbieri, et al., “Stromal cell-derived
factor-1α (SDF-1α/CXCL12) stimulates ovarian cancer cell
growth through the EGF receptor transactivation,” Experi-
mental Cell Research, vol. 308, no. 2, pp. 241–253, 2005.
[208] K. Selvendiran, A. Bratasz, L. Tong, L. J. Ignarro, and
P. Kuppusamy, “NCX-4016, a nitro-derivative of aspirin,
inhibits EGFR and STAT3 signaling and modulates Bcl-2
proteinsincisplatin-resistanthumanovariancancercellsand
xenografts,” Cell Cycle, vol. 7, no. 1, pp. 81–88, 2008.
[209] C. Zhou, L. Qiu, Y. Sun, et al., “Inhibition of EGFR/
PI3K/AKT cell survival pathway promotes TSA’s eﬀect on
cell death and migration in human ovarian cancer cells,”
International Journal of Oncology, vol. 29, no. 1, pp. 269–278,
2006.
[210] S. D. Pack, ¨ O. Alper, K. Stromberg, et al., “Simultaneous
suppression of epidermal growth factor receptor and c-erbB-
2 reverses aneuploidy and malignant phenotype of a human
ovarian carcinoma cell line,” Cancer Research, vol. 64, no. 3,
pp. 789–794, 2004.
[211] X.Zhang,M.-T.Ling,H.Feng,Y.C.Wong,S.W.Tsao,andX.
Wang, “Id-1 stimulates cell proliferation through activation
of EGFR in ovarian cancer cells,” British Journal of Cancer,
vol. 91, no. 12, pp. 2042–2047, 2004.
[212] J. V. Ilekis, J. P. Connor, G. S. Prins, K. Ferrer, C. Nieder-
berger, and B. Scoccia, “Expression of epidermal growth
factorandandrogenreceptorsinovariancancer,”Gynecologic
Oncology, vol. 66, no. 2, pp. 250–254, 1997.
[213] M. G. del Carmen, I. Rizvi, Y. Chang, et al., “Synergism of
epidermal growth factor receptor-targeted immunotherapy
with photodynamic treatment of ovarian cancer in vivo,”
Journal of the National Cancer Institute, vol. 97, no. 20, pp.
1516–1524, 2005.
[214] A. A. Kamat, T. J. Kim, C. N. Landen Jr., et al., “Metronomic
chemotherapy enhances the eﬃcacy of antivascular therapy
in ovarian cancer,” Cancer Research, vol. 67, no. 1, pp. 281–
288, 2007.
[215] S. Miyamoto, M. Hirata, A. Yamazaki, et al., “Heparin-
binding EGF-like growth factor is a promising target for
ovarian cancer therapy,” Cancer Research, vol. 64, no. 16, pp.
5720–5727, 2004.
[216] G. W. Rewcastle, D. K. Murray, W. L. Elliott, et al.,
“Tyrosine kinase inhibitors. 14. Structure-activity relation-
ships for methyl-amino-substituted derivatives of 4-[3-
bromophenyl)amino]-6-(methylaminø)-pyrido[3,4-d]pyri-
midine (PD 158780), a potent and speciﬁc inhibitor of the
tyrosine kinase activity of receptors for the EGF family of
growth factors,” Journal of Medicinal Chemistry, vol. 41, no.
5, pp. 742–751, 1998.
[217] L. Rosano, V. Di Castro, F. Spinella, et al., “Combined
targeting of endothelin a receptor and epidermal growth
factor receptor in ovarian cancer shows enhanced antitumor
activity,” Cancer Research, vol. 67, no. 13, pp. 6351–6359,
2007.
[218] P. W. Vincent, A. J. Bridges, D. J. Dykes, et al., “Anticancer
eﬃcacy of the irreversible EGFr tyrosine kinase inhibitor
PD 0169414 against human tumor xenografts,” Cancer
Chemotherapy and Pharmacology, vol. 45, no. 3, pp. 231–238,
2000.
[219] S. R. Wedge, D. J. Ogilvie, M. Dukes, et al., “ZD6474 inhibits
vascular endothelial growth factor signaling, angiogenesis,
and tumor growth following oral administration,” Cancer
Research, vol. 62, no. 16, pp. 4645–4655, 2002.